e10vq
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
|
|
|
þ |
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2007
OR
|
|
|
o |
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
COMMISSION FILE NUMBER 001-16789
INVERNESS MEDICAL INNOVATIONS, INC.
(Exact Name Of Registrant As Specified In Its Charter)
|
|
|
DELAWARE
|
|
04-3565120 |
(State or other jurisdiction of
|
|
(I.R.S. Employer |
incorporation or organization)
|
|
Identification No.) |
51 SAWYER ROAD, SUITE 200
WALTHAM, MASSACHUSETTS 02453
(Address of principal executive offices)
(781) 647-3900
(Registrants Telephone Number, Including Area Code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer,
or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in
Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated o Accelerated filer þ Non-accelerated filer filer o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act).
Yes o No þ
The number of shares outstanding of the registrants common stock, par value of $0.001 per share,
as of November 2, 2007 was 55,502,671.
INVERNESS MEDICAL INNOVATIONS, INC.
REPORT ON FORM 10-Q
For the Quarterly Period Ended September 30, 2007
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. Readers can identify these statements by forward-looking words such as
may, could, should, would, intend, will, expect, anticipate, believe, estimate,
continue or similar words. There are a number of important factors that could cause actual
results of Inverness Medical Innovations, Inc. and its subsidiaries to differ materially from those
indicated by such forward-looking statements. These factors include, but are not limited to, the
risk factors detailed in Part I, Item 1A, Risk Factors, of our Annual Report on Form 10-K for the
fiscal year ending December 31, 2006, as amended, and other risk factors identified herein or from
time to time in our periodic filings with the Securities and Exchange Commission. Readers should
carefully review these factors as well as the Special Statement Regarding Forward-Looking
Statements beginning on page 42, in this Quarterly Report on Form 10-Q and should not place undue
reliance on our forward-looking statements. These forward-looking statements are based on
information, plans and estimates at the date of this report. We undertake no obligation to update
any forward-looking statements to reflect changes in underlying assumptions or factors, new
information, future events or other changes.
Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to
we, us and our refer to Inverness Medical Innovations, Inc. and its subsidiaries.
TABLE OF CONTENTS
2
PART I FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
INVERNESS MEDICAL INNOVATIONS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
|
|
September 30, |
|
|
September 30, |
|
|
|
2007 |
|
|
2006 |
|
|
2007 |
|
|
2006 |
|
Net product sales |
|
$ |
228,568 |
|
|
$ |
140,896 |
|
|
$ |
534,521 |
|
|
$ |
400,246 |
|
License and royalty revenue |
|
|
9,068 |
|
|
|
4,016 |
|
|
|
17,059 |
|
|
|
12,200 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue |
|
|
237,636 |
|
|
|
144,912 |
|
|
|
551,580 |
|
|
|
412,446 |
|
Cost of sales |
|
|
127,338 |
|
|
|
83,767 |
|
|
|
296,604 |
|
|
|
250,551 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
|
110,298 |
|
|
|
61,145 |
|
|
|
254,976 |
|
|
|
161,895 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development (Note 12) |
|
|
20,530 |
|
|
|
11,065 |
|
|
|
44,649 |
|
|
|
34,789 |
|
Purchase of in-process research and
development (Note 13) |
|
|
169,000 |
|
|
|
4,960 |
|
|
|
169,000 |
|
|
|
4,960 |
|
Sales and marketing |
|
|
48,536 |
|
|
|
25,986 |
|
|
|
104,847 |
|
|
|
69,498 |
|
General and administrative |
|
|
28,707 |
|
|
|
18,090 |
|
|
|
119,161 |
|
|
|
51,606 |
|
Loss on dispositions, net |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,191 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating (loss) income |
|
|
(156,475 |
) |
|
|
1,044 |
|
|
|
(182,681 |
) |
|
|
(2,149 |
) |
Interest expense, including amortization of
original issue discounts and write-off of
deferred financing costs (Note 17) |
|
|
(29,041 |
) |
|
|
(8,193 |
) |
|
|
(56,238 |
) |
|
|
(20,796 |
) |
Other income (expense), net |
|
|
2,143 |
|
|
|
(1,158 |
) |
|
|
8,822 |
|
|
|
3,690 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss before (benefit) provision for
income taxes |
|
|
(183,373 |
) |
|
|
(8,307 |
) |
|
|
(230,097 |
) |
|
|
(19,255 |
) |
(Benefit) provision for income taxes |
|
|
(1,645 |
) |
|
|
1,621 |
|
|
|
1,550 |
|
|
|
3,884 |
|
Equity earnings of unconsolidated entities,
net of tax (Note 14) |
|
|
1,116 |
|
|
|
245 |
|
|
|
2,666 |
|
|
|
270 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(180,612 |
) |
|
$ |
(9,683 |
) |
|
$ |
(228,981 |
) |
|
$ |
(22,869 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common share basic and diluted
(Note 6) |
|
$ |
(3.74 |
) |
|
$ |
(0.27 |
) |
|
$ |
(4.89 |
) |
|
$ |
(0.70 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares basic and
diluted (Note 6) |
|
|
48,256 |
|
|
|
35,396 |
|
|
|
46,787 |
|
|
|
32,498 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these consolidated financial statements.
3
INVERNESS MEDICAL INNOVATIONS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except par value)
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
|
December 31, |
|
|
|
2007 |
|
|
2006 |
|
|
|
(unaudited) |
|
|
|
|
ASSETS
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
153,345 |
|
|
$ |
71,104 |
|
Marketable securities |
|
|
2,734 |
|
|
|
|
|
Accounts receivable, net of allowances of $8,360 at September 30, 2007
and $8,401 at December 31, 2006 |
|
|
122,808 |
|
|
|
100,388 |
|
Inventories, net |
|
|
136,487 |
|
|
|
78,322 |
|
Deferred tax assets |
|
|
24,152 |
|
|
|
5,332 |
|
Income taxes receivable |
|
|
28,482 |
|
|
|
3,014 |
|
Prepaid expenses and other current assets |
|
|
64,602 |
|
|
|
17,384 |
|
|
|
|
|
|
|
|
Total current assets |
|
|
532,610 |
|
|
|
275,544 |
|
Property, plant and equipment, net |
|
|
243,050 |
|
|
|
82,312 |
|
Goodwill |
|
|
1,359,951 |
|
|
|
439,369 |
|
Other intangible assets with indefinite lives |
|
|
42,937 |
|
|
|
68,107 |
|
Core technology and patents, net |
|
|
403,281 |
|
|
|
87,732 |
|
Other intangible assets, net |
|
|
655,465 |
|
|
|
83,794 |
|
Deferred financing costs, net and other non-current assets |
|
|
50,408 |
|
|
|
13,218 |
|
Investments in unconsolidated entities |
|
|
85,025 |
|
|
|
22,936 |
|
Marketable securities |
|
|
|
|
|
|
12,681 |
|
Deferred tax assets |
|
|
118,814 |
|
|
|
78 |
|
|
|
|
|
|
|
|
Total assets |
|
$ |
3,491,541 |
|
|
$ |
1,085,771 |
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS EQUITY
|
Current liabilities: |
|
|
|
|
|
|
|
|
Current portion of long-term debt |
|
$ |
8,389 |
|
|
$ |
7,504 |
|
Current portion of capital lease obligations |
|
|
583 |
|
|
|
584 |
|
Accounts payable |
|
|
57,207 |
|
|
|
46,342 |
|
Accrued expenses and other current liabilities |
|
|
151,274 |
|
|
|
87,801 |
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
217,453 |
|
|
|
142,231 |
|
|
|
|
|
|
|
|
Long-term liabilities: |
|
|
|
|
|
|
|
|
Long-term debt, net of current portion |
|
|
1,340,975 |
|
|
|
194,473 |
|
Capital lease obligations, net of current portion |
|
|
206 |
|
|
|
415 |
|
Deferred tax liabilities |
|
|
306,123 |
|
|
|
23,984 |
|
Deferred gain on joint venture |
|
|
302,514 |
|
|
|
|
|
Other long-term liabilities |
|
|
17,221 |
|
|
|
10,530 |
|
|
|
|
|
|
|
|
Total long-term liabilities |
|
|
1,967,039 |
|
|
|
229,402 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies (Note 21) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders equity: |
|
|
|
|
|
|
|
|
Preferred stock, $0.001 par value Authorized: 2,333 shares, Issued: none |
|
|
|
|
|
|
|
|
Common stock, $0.001 par value Authorized: 100,000 shares, Issued and
outstanding: 55,150 shares at September 30, 2007 and 39,215 shares at
December 31, 2006 |
|
|
55 |
|
|
|
39 |
|
Additional paid-in capital |
|
|
1,637,692 |
|
|
|
826,987 |
|
Accumulated deficit |
|
|
(356,050 |
) |
|
|
(127,069 |
) |
Accumulated other comprehensive income |
|
|
25,352 |
|
|
|
14,181 |
|
|
|
|
|
|
|
|
Total stockholders equity |
|
|
1,307,049 |
|
|
|
714,138 |
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity |
|
$ |
3,491,541 |
|
|
$ |
1,085,771 |
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these consolidated financial statements.
4
INVERNESS MEDICAL INNOVATIONS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended |
|
|
|
September 30, |
|
|
|
2007 |
|
|
2006 |
|
Cash Flows from Operating Activities: |
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(228,981 |
) |
|
$ |
(22,869 |
) |
Adjustments to reconcile net loss to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
Interest expense related to amortization of non-cash original issue
discount and amortization and write-off of deferred financing costs |
|
|
9,549 |
|
|
|
3,252 |
|
Non-cash income related to currency hedge |
|
|
|
|
|
|
(217 |
) |
Non-cash stock-based compensation expense |
|
|
46,926 |
|
|
|
3,872 |
|
Charge for in-process research and development |
|
|
169,000 |
|
|
|
4,960 |
|
Loss on sale of fixed assets |
|
|
156 |
|
|
|
|
|
Interest in minority investments |
|
|
(1,264 |
) |
|
|
|
|
Depreciation and amortization |
|
|
61,604 |
|
|
|
29,213 |
|
Deferred and other non-cash income taxes |
|
|
7,046 |
|
|
|
1,860 |
|
Impairment of long-lived assets |
|
|
|
|
|
|
9,143 |
|
Other non-cash items |
|
|
31 |
|
|
|
(1,517 |
) |
Changes in assets and liabilities, net of acquisitions: |
|
|
|
|
|
|
|
|
Accounts receivable, net |
|
|
41,684 |
|
|
|
(25,019 |
) |
Inventories, net |
|
|
(7,104 |
) |
|
|
(8,607 |
) |
Prepaid expenses and other current assets |
|
|
(21,851 |
) |
|
|
3,067 |
|
Accounts payable |
|
|
(6,735 |
) |
|
|
16,202 |
|
Accrued expenses and other current liabilities |
|
|
(30,734 |
) |
|
|
(6,681 |
) |
Other non-current liabilities |
|
|
(5,302 |
) |
|
|
224 |
|
|
|
|
|
|
|
|
Net cash provided by operating activities |
|
|
34,025 |
|
|
|
6,883 |
|
|
|
|
|
|
|
|
Cash Flows from Investing Activities: |
|
|
|
|
|
|
|
|
Purchases of property, plant and equipment |
|
|
(21,711 |
) |
|
|
(13,557 |
) |
Proceeds from sale of equipment |
|
|
170 |
|
|
|
2,217 |
|
Cash paid for acquisitions and transactional costs, net of cash acquired |
|
|
(1,590,107 |
) |
|
|
(124,395 |
) |
Cash received, net of cash paid, to form joint venture |
|
|
324,170 |
|
|
|
|
|
Cash paid for minority interest investments |
|
|
(13,446 |
) |
|
|
|
|
Increase in other assets |
|
|
(29,509 |
) |
|
|
(2,031 |
) |
|
|
|
|
|
|
|
Net cash used in investing activities |
|
|
(1,330,433 |
) |
|
|
(137,766 |
) |
|
|
|
|
|
|
|
Cash Flows from Financing Activities: |
|
|
|
|
|
|
|
|
Cash paid for financing costs |
|
|
(38,100 |
) |
|
|
(2,012 |
) |
Proceeds from issuance of common stock, net of issuance costs |
|
|
300,901 |
|
|
|
231,333 |
|
Net proceeds (payments) of long-term debt |
|
|
1,131,088 |
|
|
|
(45,127 |
) |
Payments on short-term note payable |
|
|
(22,326 |
) |
|
|
(22,614 |
) |
Payments received on note receivable |
|
|
|
|
|
|
10,665 |
|
Tax benefit on exercised stock options |
|
|
625 |
|
|
|
|
|
Principal payments of capital lease obligations |
|
|
(427 |
) |
|
|
(409 |
) |
|
|
|
|
|
|
|
Net cash provided by financing activities |
|
|
1,371,761 |
|
|
|
171,836 |
|
|
|
|
|
|
|
|
Foreign exchange effect on cash and cash equivalents |
|
|
6,888 |
|
|
|
(651 |
) |
|
|
|
|
|
|
|
Net increase in cash and cash equivalents |
|
|
82,241 |
|
|
|
40,302 |
|
Cash and cash equivalents, beginning of period |
|
|
71,104 |
|
|
|
34,270 |
|
|
|
|
|
|
|
|
Cash and cash equivalents, end of period |
|
$ |
153,345 |
|
|
$ |
74,572 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental Disclosure of Non-cash Activities: |
|
|
|
|
|
|
|
|
Fair value of stock issued for acquisitions |
|
$ |
357,346 |
|
|
$ |
68,915 |
|
|
|
|
|
|
|
|
Fair value associated with Biosite and Cholestech employee stock
options assumed |
|
$ |
86,162 |
|
|
$ |
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these consolidated financial statements.
5
INVERNESS MEDICAL INNOVATIONS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(1) Basis of Presentation of Financial Information
The accompanying consolidated financial statements of Inverness Medical Innovations, Inc. and
its subsidiaries are unaudited. In the opinion of management, the unaudited consolidated financial
statements contain all adjustments considered normal and recurring and necessary for their fair
presentation. Interim results are not necessarily indicative of results to be expected for the
year. These interim financial statements have been prepared in accordance with accounting
principles generally accepted in the United States of America for interim financial information and
in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly,
these consolidated financial statements do not include all of the information and footnotes
necessary for a complete presentation of financial position, results of operations and cash flows.
Our audited consolidated financial statements for the year ended December 31, 2006 included
information and footnotes necessary for such presentation and were included in our Annual Report on
Form 10-K/A filed with the Securities and Exchange Commission on March 26, 2007. These unaudited
consolidated financial statements should be read in conjunction with our audited consolidated
financial statements and notes thereto for the year ended December 31, 2006.
(2) Cash and Cash Equivalents
We consider all highly liquid cash investments with original maturities of three months or
less at the date of acquisition to be cash equivalents. At September 30, 2007, our cash equivalents
consisted of money market funds.
(3) Inventories
Inventories are stated at the lower of cost (first in, first out) or market and are comprised
of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
September 30, 2007 |
|
|
December 31, 2006 |
|
Raw materials |
|
$ |
42,036 |
|
|
$ |
29,372 |
|
Work-in-process |
|
|
38,406 |
|
|
|
19,080 |
|
Finished goods |
|
|
56,045 |
|
|
|
29,870 |
|
|
|
|
|
|
|
|
|
|
$ |
136,487 |
|
|
$ |
78,322 |
|
|
|
|
|
|
|
|
(4) Income Tax Receivable
Income tax receivable at September 30, 2007 was $28.5 million. This income tax receivable is
primarily related to a U.S. tax loss of Biosite Incorporated (Biosite). This tax loss will
generate refunds of 2007 state income taxes paid as of September 30, 2007 and tax refunds for 2004,
2005 and 2006 federal tax carryback claims.
(5) Stock-Based Compensation
Effective January 1, 2006, we began recording compensation expense associated with stock
options and other forms of equity compensation in accordance with Statement of Financial Accounting
Standards (SFAS) No. 123-R, Share-Based Payment, as interpreted by SEC Staff Accounting Bulletin
No. 107. Prior to January 1, 2006, we accounted for stock options according to the provisions of
Accounting Principles Board (APB) Opinion No. 25, Accounting for Stock Issued to Employees, and
related interpretations, and therefore no related compensation expense was recorded for awards
granted with no intrinsic value. We adopted the modified prospective transition method provided for
under SFAS No. 123-R, and consequently have not retroactively adjusted results from prior periods.
Under this transition method, compensation cost associated with stock options now includes: (i)
amortization related to the remaining unvested portion of all stock option awards granted prior to
January 1, 2006, based on the grant-date fair value estimated in accordance with the original
provisions of SFAS No. 123, and (ii) amortization related to all stock option awards granted
subsequent to January 1, 2006, based on the grant-date fair value estimated in accordance with the
provisions of SFAS 123-R. In addition, we record expense over the offering period in connection
with shares issued under our employee stock purchase plan. The compensation expense for stock-based
compensation awards includes an estimate for forfeitures and is recognized over the expected term
of the options using the straight-line method.
6
INVERNESS MEDICAL INNOVATIONS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Continued
(unaudited)
In accordance with SFAS No. 123-R, as of September 30, 2007, our results of operations
reflected compensation expense for new stock options granted and vested under our stock incentive
plan and employee stock purchase plan during the three and nine months ended September 30, 2007 and
2006 and the unvested portion of previous stock option grants which vested during the first nine
months of 2007 and 2006. Stock-based compensation expense in the amount of $3.3 million ($2.3
million, net of tax) and $52.2 million ($49.0 million, net of tax) and $1.3 million ($1.3 million,
net of tax) and $3.9 million ($3.5 million, net of tax) was reflected in the consolidated statement
of operations for the three and nine months ended September 30, 2007 and 2006, respectively, as
follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Nine months ended |
|
|
|
September 30, |
|
|
September 30, |
|
|
|
2007 |
|
|
2006 |
|
|
2007 |
|
|
2006 |
|
Cost of sales |
|
$ |
119 |
|
|
$ |
89 |
|
|
$ |
317 |
|
|
$ |
284 |
|
Research and development |
|
|
612 |
|
|
|
301 |
|
|
|
1,301 |
|
|
|
858 |
|
Sales and marketing |
|
|
351 |
|
|
|
101 |
|
|
|
1,043 |
|
|
|
444 |
|
General and administrative |
|
|
2,201 |
|
|
|
823 |
|
|
|
49,535 |
|
|
|
2,272 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
3,283 |
|
|
$ |
1,314 |
|
|
$ |
52,196 |
|
|
$ |
3,858 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Included in the amount above for general and administrative expense for the nine months ended
September 30, 2007, is $45.2 million related to our assumption of Biosite options.
The expense relates to the acceleration of unvested Biosite employee options. See Note 10(b)
regarding our acquisition of Biosite.
In connection with our acquisition of Cholestech Corporation (Cholestech), we assumed
unvested restricted stock awards for which we issued 38,479 restricted shares of our common stock. The expense
recognition for such awards is consistent with the treatment of our other stock-based compensation
awards as described above. Included in the $3.3 million and $52.2 million for the three and nine
months ended September 30, 2007, respectively, is $17,000 related to the vesting of these shares.
In accordance with SFAS No. 123-R, we report the excess tax benefits from the exercise of
stock options as financing cash flows. For the three months ended September 30, 2007 and 2006,
there was $0.3 million and $0, respectively, of excess tax benefits generated from option
exercises. For the nine months ended September 30, 2007 and 2006, there was $0.6 million and $0,
respectively, of excess tax benefits generated from option exercises.
Our stock option plans provide for grants of options to employees to purchase common stock at
the fair market value of such shares on the grant date of the award. The options vest over a four
year period, beginning on the date of grant, with a graded vesting schedule of 25% at the end of
each of the four years. The fair value of each option grant is estimated on the date of grant using
the Black-Scholes option-pricing method. We use historical data to estimate the expected price
volatility and the expected forfeiture rate. For the three and nine months ended September 30, 2007
and 2006, we have chosen to employ the simplified method of calculating the expected option term,
which averages an awards weighted average vesting period and its contractual term. The contractual
term of our stock option awards is ten years. The risk-free rate is based on the U.S. Treasury
yield curve in effect at the time of grant with a remaining term equal to the expected term of the
option. We have not made any dividend payments nor do we have plans to pay dividends in the
foreseeable future. The following assumptions were used to estimate the fair value of options
granted during the three and nine months ended September 30, 2007 and 2006 using the Black-Scholes
option-pricing model:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
Stock Options: |
|
2007 |
|
2006 |
|
2007 |
|
2006 |
Risk-free interest rate |
|
|
4.45 |
% |
|
|
4.00 |
% |
|
|
4.45% 5.00 |
% |
|
|
4.00% 4.38 |
% |
Expected dividend yield |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expected term |
|
6.25 years |
|
6.25 years |
|
6.25 years |
|
6.25 years |
Expected volatility |
|
|
43.83 |
% |
|
|
42 |
% |
|
|
43.83% |
|
|
|
42% |
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
Employee Stock Purchase Plan: |
|
2007 |
|
2006 |
|
2007 |
|
2006 |
Risk-free interest rate |
|
|
4.17 |
|
|
|
4.99 |
% |
|
|
4.17% |
|
|
|
4.99% |
|
Expected dividend yield |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expected term |
|
184 days |
|
184 days |
|
184 days |
|
184 days |
Expected volatility |
|
|
69.49 |
% |
|
|
33.19 |
% |
|
|
69.49% |
|
|
|
33.19% |
|
A summary of the stock option activity for the nine months ended September 30, 2007 is as
follows (in thousands, except exercise price and contractual term):
7
INVERNESS MEDICAL INNOVATIONS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Continued
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted |
|
|
|
|
|
|
|
|
|
|
|
|
Average |
|
|
|
|
|
|
|
|
Weighted |
|
Remaining |
|
|
|
|
|
|
|
|
Average Exercise |
|
Contractual |
|
Aggregate |
|
|
Options |
|
Price |
|
Term |
|
Intrinsic value |
Options outstanding, January 1, 2007 |
|
|
3,775 |
|
|
$ |
21.11 |
|
|
|
|
|
|
|
Acquired(1) |
|
|
2,845 |
|
|
$ |
26.63 |
|
|
|
|
|
|
|
Granted |
|
|
1,673 |
|
|
$ |
44.10 |
|
|
|
|
|
|
|
Exercised |
|
|
(1,503 |
) |
|
$ |
25.32 |
|
|
|
|
|
|
|
Canceled/forfeited/expired |
|
|
(93 |
) |
|
$ |
34.33 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options outstanding, September 30, 2007 |
|
|
6,697 |
|
|
$ |
28.07 |
|
|
6.60 years |
|
$ |
182,623 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options exercisable, September 30, 2007 |
|
|
3,923 |
|
|
$ |
20.89 |
|
|
4.92 years |
|
$ |
135,174 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Acquired with the acquisitions of Biosite and Cholestech. |
The weighted average fair value under the Black-Scholes option pricing model of options
granted to employees during the nine months ended September 30, 2007 and 2006 was $21.57 per share
and $12.93 per share, respectively.
The aggregate intrinsic value of stock options exercised during the three and nine months
ended September 30, 2007 was $32.7 million and $36.5 million, respectively.
Based on equity awards outstanding as of September 30, 2007, there was $46.4 million of
unrecognized compensation costs related to unvested share-based compensation arrangements that are
expected to vest. Such costs are expected to be recognized over a weighted average period of 3.14
years.
(6) Net Loss Per Common Share
The following table sets forth the computation of basic and diluted net loss per common share
(in thousands, except per share amounts):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
|
|
September 30, |
|
|
September 30, |
|
|
|
2007 |
|
|
2006 |
|
|
2007 |
|
|
2006 |
|
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss applicable to common stock holders
basic and diluted |
|
$ |
(180,612 |
) |
|
$ |
(9,683 |
) |
|
$ |
(228,981 |
) |
|
$ |
(22,869 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator for basic and diluted net loss
per common share weighted average shares |
|
|
48,256 |
|
|
|
35,396 |
|
|
|
46,787 |
|
|
|
32,498 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common share basic and diluted |
|
$ |
(3.74 |
) |
|
$ |
(0.27 |
) |
|
$ |
(4.89 |
) |
|
$ |
(0.70 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
We had the following potential dilutive securities outstanding on September 30, 2007: options
and warrants to purchase an aggregate of 7,002,267 shares of common stock at a weighted average
exercise price of $27.56 per share and 3% convertible notes, convertible at $52.30, which represent
an aggregate 2,868,120 shares, if converted. These potential dilutive securities were not included
in the computation of diluted net loss per common share because the effect of including such
potential dilutive securities would be anti-dilutive.
We had the following potential dilutive securities outstanding on September 30, 2006: options
and warrants to purchase an aggregate of 4,316,816 shares of common stock at a weighted average
exercise price of $19.90 per share. These potential dilutive securities were not included in the
computation of diluted net loss per common share because the effect of including such potential
dilutive securities would be anti-dilutive.
(7) Uncertain Income Tax Positions
We adopted Financial Accounting Standards Board (FASB) Interpretation No. 48 (FIN 48),
Accounting for Uncertainty in Income Taxes an Interpretation of FASB Statement 109 on January 1,
2007. The cumulative effect
of adopting FIN 48 had no change to the January 1, 2007 retained earnings balance. Upon
adoption, the liability for
8
INVERNESS MEDICAL INNOVATIONS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Continued
(unaudited)
income taxes associated with uncertain tax positions at January 1, 2007
was $2.2 million. This amount of $2.2 million, if recognized, would favorably affect our effective
tax rate. In addition, consistent with the provisions of FIN 48, we classified $2.2 million of
income tax liabilities as non-current income tax liabilities because a payment of cash is not
anticipated within one year of balance sheet date. During the nine month period ending September
30, 2007, we increased the liability for income taxes associated with uncertain tax positions by
$6.7 million for a total of $8.9 million at September 30, 2007. Of the $6.7 million increase, $6.3 million is related to Biosites uncertain tax positions which we assumed at the date of acquisition. These non-current income tax liabilities are recorded
in other long-term liabilities in our consolidated balance sheet at September 30, 2007. We
anticipate periodic increases to the total amount of unrecognized tax benefits as our business continues to expand.
Interest and penalties related to income tax liabilities are included in income tax expense.
The balance of accrued interest and penalties recorded in the consolidated balance sheet at
September 30, 2007 was $0.2 million.
With limited exception, we are subject to U.S. federal, state and local or non-U.S. income tax
audits by tax authorities for all years. We are currently under income tax examination by a number
of state and foreign tax authorities and anticipate these audits will be completed by the end of
2008.
(8) Comprehensive Income (Loss)
We account for comprehensive income (loss) as prescribed by SFAS No. 130, Reporting
Comprehensive Income. In general, comprehensive income (loss) combines net income (loss) and other
changes in equity during the year from non-owner sources. Our accumulated other comprehensive
income, which is a component of shareholders equity, includes primarily foreign currency
translation adjustments and is our only source of equity from non-owners. For the three and nine
months ended September 30, 2007, we generated a comprehensive loss of $174.0 million and $217.8
million, respectively, and for the three and nine months ended September 30, 2006, we generated a
comprehensive loss of $6.4 million and $17.4 million, respectively.
The consolidated statements of stockholders equity and comprehensive income (loss) for the
year ended December 31, 2006 set forth in our Annual Report on Form 10-K/A for the year ended
December 31, 2006 included an incorrect presentation of the adoption of SFAS 158, Employers
Accounting for Defined Benefit Pension and Other Postretirement Plans An Amendment of FASB
Statements No. 87, 88, 106 and 132(R). The presentation included a $3.7 million charge for the
impact of the adoption as a component of current-period other comprehensive income rather than
displaying the adoption impact as an adjustment to accumulated other comprehensive income.
We will correct the consolidated statement of stockholders equity and comprehensive income
(loss) for the year ended December 31, 2006 in our Annual Report on Form 10-K for the year ending
December 31, 2007. The revision will have no impact on net income, total accumulated other
comprehensive income, total assets or cash flows for the year ended December 31, 2006.
(9) Stockholders Equity
We raised net proceeds of approximately $261.3 million through an underwritten public offering
of 6,900,000 shares of our common stock. In January 2007, we sold 6,000,000 shares to the public at
$39.65 per share, and in February 2007, our underwriters exercised in full an option to purchase an
additional 900,000 shares to cover over-allotments. Net proceeds include deductions for
underwriting discounts and commissions and take into effect the reimbursement by the underwriters
of a portion of our offering expenses. Of this amount, we used $44.9 million to repay principal
outstanding and accrued interest on our term loan under our senior credit facility, with the
remainder of the net proceeds retained for working capital and other general corporate purposes,
including the financing of acquisitions and other investments.
(10) Business Combinations
Acquisitions are an important part of our growth strategy. When we acquire businesses, we seek
to complement existing products and services, enhance or expand our product lines and/or expand our
customer base. We determine
what we are willing to pay for each acquisition partially based on our expectation that we can
cost effectively
9
INVERNESS MEDICAL INNOVATIONS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Continued
(unaudited)
integrate the products and services of the acquired companies into our existing
infrastructure. In addition, we utilize existing infrastructure of the acquired companies to cost
effectively introduce our products to new geographic areas.
We account for our acquisitions using the purchase method of accounting as defined under SFAS
No. 141, Business Combinations. Accordingly, the operating results of the acquired company are
included in our consolidated financial statements of operations after the acquisition date as part
of the reporting unit to which it relates. Accounting for these acquisitions has resulted in the
capitalization of the cost in excess of fair value of the net assets acquired in each of these
acquisitions as goodwill. We estimated the fair values of the assets acquired and liabilities
assumed in each acquisition as of the date of acquisition and these estimates are subject to
adjustment. We complete these assessments within one year of the date of acquisition. We have
undertaken certain restructurings of the acquired businesses to realize efficiencies and
potential cost savings. Our restructuring activities include the elimination of duplicate
facilities, reductions in staffing levels, and other costs associated with exiting
certain activities of the businesses we acquire. The estimated cost of
these restructuring activities are included as costs of the acquisition and
are recorded as additional purchase price consistent with the guidance of
Emerging Issue Task Force (EITF) Issue No. 95-3, Recognition of Liabilities
in Connection with a Purchase Business Combination. Any common stock issued with our
acquisitions is determined based on the average market price of our common stock pursuant to
EITF Issue No. 99-12, Determination of the Measurement Date for the Market Price of Acquirer
Securities Issued in a Purchase Business Combination.
(a) Acquisition of Cholestech Corporation
On September 12, 2007, we acquired Cholestech, a publicly-traded
leading provider of diagnostic tools and information for immediate risk assessment and therapeutic
monitoring of heart disease and inflammatory disorders. The preliminary aggregate purchase price
was $358.7 million, which consisted of 6,840,361 shares of our common stock with an aggregate fair
value of $329.8 million, $4.3 million for direct acquisition costs, estimated exit costs of $4.3
million and $20.3 million of fair value associated with the outstanding fully-vested Cholestech
employee stock options which were converted to options to acquire our common stock as part of the
transaction. We expect to incur a write-off of in-process research and development (IPR&D)
projects that have not yet achieved technological feasibility as of the date of our acquisition of
Cholestech and will record the charge through purchase accounting once this amount is determined.
We evaluated the business and formulated a restructuring plan which is consistent with our
acquisition strategy to realize efficiencies and cost savings. We communicated our plan during the
third and fourth quarters of 2007.
The preliminary aggregate purchase price was allocated to the assets acquired and assumed
liabilities at the date of acquisition as follows (amounts in thousands, except share data):
|
|
|
|
|
Cash and cash equivalents |
|
$ |
66,521 |
|
Accounts receivable |
|
|
4,879 |
|
Inventories |
|
|
10,805 |
|
Other current assets |
|
|
1,522 |
|
Property, plant and equipment |
|
|
6,677 |
|
Goodwill |
|
|
72,279 |
|
Trademarks |
|
|
20,590 |
|
Customer relationships |
|
|
99,250 |
|
Core technology |
|
|
83,810 |
|
Internally-developed software |
|
|
200 |
|
Other non-current assets |
|
|
1,047 |
|
Accounts payable and accrued expenses |
|
|
(8,152 |
) |
Deferred tax liability |
|
|
(749 |
) |
|
|
|
|
|
|
$ |
358,679 |
|
|
|
|
|
The preliminary aggregate purchase price, as adjusted, was allocated to the tangible and
intangible assets acquired and liabilities assumed based on their estimated fair values at the date
of acquisition. Management has assigned an estimated useful life of 10 years, 26 years, 13 years
and 7 years to trademarks, customer relationships, core technology and internally-developed
software, respectively, and has recorded these assets in core technology
and patents, net and other intangible assets, net in the accompanying consolidated balance
sheet at September 30,
10
INVERNESS MEDICAL INNOVATIONS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Continued
(unaudited)
2007. The excess of the purchase price over the estimated fair value of the
assets acquired and liabilities assumed was allocated to goodwill. We expect that substantially all
of the amount allocated to goodwill will not be deductible for tax purposes. The allocation of
purchase price remains subject to potential adjustments, including adjustments for liabilities
associated with certain exit activities and restructuring activities.
The operating results of Cholestech are included in our cardiology reporting unit of our
professional diagnostic products business segment.
(b) Acquisition of Biosite Incorporated
On June 29, 2007, we completed our acquisition of Biosite, a publicly-traded global medical
diagnostic company utilizing a biotechnology approach to create products for the diagnosis of
critical diseases and conditions. The preliminary aggregate purchase price was $1.8 billion, which
consisted of $1.6 billion in cash, $68.4 million in
estimated direct acquisition costs, $12.4
million in estimated exit costs and $77.4 million of fair value associated with the outstanding
fully-vested Biosite employee stock options which were converted to options to acquire our common
stock as part of the transaction.
Furthermore, we evaluated the business and formulated a restructuring plan which is consistent with
our acquisition strategy to realize efficiencies and cost savings. We communicated our plan during
the third and fourth quarters of 2007.
The preliminary aggregate purchase price was allocated to the assets acquired and liabilities
assumed at the date of acquisition as follows (in thousands):
|
|
|
|
|
Cash and cash equivalents |
|
$ |
174,115 |
|
Accounts receivable |
|
|
44,386 |
|
Inventories |
|
|
39,557 |
|
Deferred tax asset |
|
|
18,691 |
|
Other current assets |
|
|
40,903 |
|
Property, plant and equipment |
|
|
147,104 |
|
Goodwill |
|
|
727,767 |
|
Trademarks |
|
|
78,100 |
|
Customer relationships |
|
|
348,100 |
|
Core technology |
|
|
175,850 |
|
Patents and licenses |
|
|
63,230 |
|
In-process research and development |
|
|
169,000 |
|
Deferred tax asset |
|
|
101,734 |
|
Other non-current assets |
|
|
5,009 |
|
Accounts payable and accrued expenses |
|
|
(55,179 |
) |
Other long-term liabilities |
|
|
(8,496 |
) |
Deferred tax liability |
|
|
(268,688 |
) |
|
|
|
|
|
|
$ |
1,801,183 |
|
|
|
|
|
As
part of the purchase price allocation, IPR&D projects have been
valued at $169.0 million. These are projects that have not yet
achieved technological feasibility as of the date of our acquisition
of Biosite.
The preliminary aggregate purchase price, as adjusted, was allocated to the tangible and
intangible assets acquired and liabilities assumed based on their estimated fair values at the date
of acquisition. Management has assigned an estimated useful life of 10.5 years for trademarks, a
range of 1.5 years to 22.5 years for customer relationships, a range of 11.5 years to 19.5 years
for core technology, and a range of 11.5 years to 14.5 years to patents and licenses and has
recorded these assets in core technology and patents, net and other intangible assets, net in the
accompanying consolidated balance sheet at September 30, 2007. The excess of the purchase price
over the estimated fair value of the assets acquired and liabilities assumed was allocated to
goodwill. We expect that substantially all of the amount allocated to goodwill will not be
deductible for tax purposes. The allocation of purchase price remains subject to potential
adjustments, including adjustments for liabilities associated with certain exit activities and restructuring activities.
The operating results of Biosite are included in our cardiology reporting unit of our
professional diagnostic products business segment.
11
INVERNESS MEDICAL INNOVATIONS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Continued
(unaudited)
(c) Acquisition of Quality Assurance Services, Inc.
On June 7, 2007, we acquired Quality Assurance Services, Inc. (QAS), a privately-owned
provider of diagnostic home tests and services in the U.S. marketplace. The preliminary aggregate
purchase price was $25.4 million, which consisted of $12.5 million in cash, 273,642 shares of our
common stock with an aggregate fair value of $12.8 million and
$0.1 million in direct acquisition costs
The preliminary aggregate purchase price was allocated to the assets acquired and liabilities
assumed at the date of acquisition as follows (in thousands):
|
|
|
|
|
Cash and cash equivalents |
|
$ |
110 |
|
Accounts receivable |
|
|
3,038 |
|
Inventories |
|
|
470 |
|
Other current assets |
|
|
24 |
|
Property, plant and equipment |
|
|
1,198 |
|
Goodwill |
|
|
19,866 |
|
Trademarks |
|
|
2,500 |
|
Customer relationships |
|
|
1,700 |
|
Internally-developed software |
|
|
1,910 |
|
Deferred tax asset |
|
|
29 |
|
Accounts payable and accrued expenses |
|
|
(3,561 |
) |
Long-term debt |
|
|
(1,862 |
) |
|
|
|
|
|
|
$ |
25,422 |
|
|
|
|
|
The preliminary aggregate purchase price, as adjusted, was allocated to the tangible and
intangible assets acquired and liabilities assumed based on their estimated fair values at the date
of acquisition. Management has assigned an estimated useful life of 5 years, 11 years and 7 years
to trademarks, customer relationships and internally-developed software, respectively, and has
recorded these assets in other intangible assets, net in the accompanying consolidated balance
sheet at September 30, 2007. The excess of the purchase price over the estimated fair value of the
assets acquired and liabilities assumed was allocated to goodwill. We expect that the amount
allocated to goodwill will not be deductible for tax purposes. The allocation of purchase price
remains subject to potential adjustments.
The operating results of QAS are included in our professional diagnostic products reporting
unit and business segment.
(d) Acquisition of Instant Technologies, Inc.
On March 12, 2007, we acquired 75% of the issued and outstanding capital stock of Instant
Technologies, Inc. (Instant), a privately-owned distributor of rapid drugs of abuse diagnostic
products used in the workplace, criminal justice and other testing markets. The aggregate purchase
price was $44.1 million, which consisted of $30.6 million in cash, 313,888 shares of our common
stock with an aggregate fair value of $13.1 million and $0.4 million in direct acquisition costs.
The aggregate purchase price was allocated to the assets acquired and liabilities assumed at
the date of acquisition as follows (in thousands):
|
|
|
|
|
Cash and cash equivalents |
|
$ |
327 |
|
Accounts receivable |
|
|
3,638 |
|
Inventories |
|
|
4,267 |
|
Other current assets |
|
|
780 |
|
Property, plant and equipment |
|
|
141 |
|
Goodwill |
|
|
32,934 |
|
Trademarks |
|
|
2,380 |
|
Customer relationships |
|
|
19,010 |
|
Accounts payable and accrued expenses |
|
|
(4,279 |
) |
12
INVERNESS MEDICAL INNOVATIONS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Continued
(unaudited)
|
|
|
|
|
Long-term debt |
|
|
(4,925 |
) |
Other long-term liability |
|
|
(1,220 |
) |
Deferred tax liability |
|
|
(8,976 |
) |
|
|
|
|
|
|
$ |
44,077 |
|
|
|
|
|
The above values for the assets acquired and liabilities assumed are based on final
valuations. We estimate a useful life of 5 years and 12 years to trademarks and customer
relationships, respectively, and have recorded these assets in other intangible assets, net in the
accompanying consolidated balance sheet at September 30, 2007. The excess of the purchase price
over the estimated fair value of the assets acquired and liabilities assumed was allocated to
goodwill. We expect that the amount allocated to goodwill will not be deductible for tax purposes.
The allocation of purchase price remains subject to potential adjustments.
The operating results of Instant are included in our professional diagnostic products
reporting unit and business segment and the 25% minority interest is recorded in other long-term
liabilities on our consolidated balance sheet at September 30, 2007.
(e) Acquisition of First Check Diagnostics LLC
On January 31, 2007, we acquired substantially all of the net assets of First Check
Diagnostics LLC (First Check), a privately-held diagnostics company in the field of home testing
for drugs of abuse, including marijuana, cocaine, methamphetamines and opiates. The aggregate
purchase price was approximately $24.8 million, which consisted of $24.5 million in cash and $0.2
million in direct acquisition costs.
The aggregate purchase price was allocated to the assets acquired and liabilities assumed at
the date of acquisition as follows (in thousands):
|
|
|
|
|
Accounts receivable |
|
$ |
1,539 |
|
Inventories |
|
|
638 |
|
Other current assets |
|
|
61 |
|
Property, plant and equipment |
|
|
6 |
|
Goodwill |
|
|
6,406 |
|
Trademarks |
|
|
1,438 |
|
Customer relationships |
|
|
15,145 |
|
Non-compete agreements |
|
|
438 |
|
Accounts payable and accrued expenses |
|
|
(909 |
) |
|
|
|
|
|
|
$ |
24,762 |
|
|
|
|
|
The above values for the assets acquired and liabilities assumed are based on final
valuations. We estimate a useful life of 5 years, 10 years and 4 years for trademarks, customer
relationships and the non-compete agreements, respectively, and have recorded these assets in other
intangible assets, net in the accompanying consolidated balance sheet at September 30, 2007. The
excess of the purchase price over the estimated fair value of the assets acquired and liabilities
assumed was allocated to goodwill. We expect that the amount allocated to goodwill will be
deductible for tax purposes. The allocation of purchase price remains subject to potential
adjustments.
The operating results of First Check are included in our consumer diagnostic products
reporting unit and business segment.
(f) Various Other Acquisitions
During the nine months period ending September 30, 2007, we acquired the following businesses
for an aggregate purchase price of $25.4 million, in which we paid in $23.8 million in cash and
issued 40,186 shares of our common stock with an aggregate fair value of $1.6 million:
|
|
|
Spectral Diagnostics Private Limited and its affiliate Source Diagnostics (India) Private
Limited (Spectral/Source), located in New Delhi and Shimla, India, distributes
professional diagnostic products in India |
13
INVERNESS MEDICAL INNOVATIONS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Continued
(unaudited)
|
|
|
52.45% share in Diamics, Inc. (Diamics), located in Novato, California, develops
molecular-based cancer screening and diagnostic systems |
|
|
|
|
Orange Medical (Orange), located in Tilburg, The Netherlands, a manufacturer and
marketer of rapid diagnostic products to the Benelux marketplace |
|
|
|
|
Promesan S.r.l. (Promesan), located in Milan, Italy, a distributor of point-of-care
diagnostic testing products to the Italian marketplace |
|
|
|
|
the assets of Nihon Schering K.K. (NSKK), located in Japan, a diagnostic distribution
business |
|
|
|
|
Gabmed, located in Nettetal, Germany, a distributor of point-of care diagnostic testing
products in the German marketplace |
|
|
|
|
Med-Ox Chemicals Limited (Med-Ox), located in Ottawa, Canada, a distributor of
professional diagnostic testing products in the Canadian marketplace |
NSKK and Promesan are included in our consumer and professional diagnostic products reporting
units and business segments and Spectral/Source, Orange, Gabmed and Med-Ox are included in our
professional diagnostic products reporting unit and business segment. Diamics is fully consolidated
and included in our professional diagnostic products reporting unit and business segment and the
25% minority interest is recorded in other long-term liabilities on our consolidated balance sheet
at September 30, 2007. Goodwill has been recognized in the Spectral/Source, Diamics, Orange,
Gabmed, Promesan and Med-Ox transactions and amounted to approximately $17.0 million. Goodwill
related to these acquisitions is not deductible for tax purposes.
(g) Restructuring Plans of Acquisitions
In connection with several of our acquisitions, we initiated integration plans to consolidate
and restructure certain functions and operations, including the relocation and termination of
certain personnel of these acquired entities and the closure of certain of the acquired entities
leased facilities. These costs have been recognized as liabilities assumed in connection with the
acquisition of these entities in accordance with EITF Issue No. 95-3 and are subject to potential
adjustments as certain exit activities are confirmed or refined. The following table summarizes
the liabilities established for exit activities related to these acquisitions
(amounts in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Severance |
|
|
Facility |
|
|
Total Exit |
|
|
|
Related |
|
|
And Other |
|
|
Activities |
|
Balance at December 31, 2005 |
|
$ |
1,489 |
|
|
$ |
939 |
|
|
$ |
2,428 |
|
Payments |
|
|
(172 |
) |
|
|
(150 |
) |
|
|
(322 |
) |
Currency adjustments |
|
|
177 |
|
|
|
|
|
|
|
177 |
|
|
|
|
|
|
|
|
|
|
|
Balance at
December 31, 2006 |
|
|
1,494 |
|
|
|
789 |
|
|
|
2,283 |
|
Acquisitions |
|
|
16,695 |
|
|
|
20 |
|
|
|
16,715 |
|
Payments |
|
|
(3,029 |
) |
|
|
(118 |
) |
|
|
(3,147 |
) |
Currency adjustments |
|
|
48 |
|
|
|
|
|
|
|
48 |
|
|
|
|
|
|
|
|
|
|
|
Balance at
September 30, 2007 |
|
$ |
15,208 |
|
|
$ |
691 |
|
|
$ |
15,899 |
|
|
|
|
|
|
|
|
|
|
|
In
conjunction with our acquisition of Biosite, we implemented an integration plan to improve
efficiencies and eliminate redundant costs resulting from the acquisition. The restructuring plan
impacted all cost centers within the Biosite organization, as activities were combined with our
existing business operations. We recorded $12.4 million in exit
costs, of which
substantially all relate to change in control and severance costs to involuntarily terminate 137 employees in the
Biosite organization.
Additionally, we formulated a restructuring plan
in connection with our integration of the Cholestech business
consistent with our acquisition strategy to realize efficiencies and
cost savings and recorded $4.3 million in exit costs related
14
INVERNESS MEDICAL INNOVATIONS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Continued
(unaudited)
to change in control and severance costs to
involuntarily terminate 29 employees, primarily executives.
(11) Restructuring Plans
(a) 2007 Restructuring Plans
In
September 2007, we committed to a plan to improve efficiencies
in operations resulting in the termination of certain employees at
our headquarters in Waltham, Massachusetts, who were performing research and
development related services for our research center in Stirling,
Scotland. During the three months ended September 30, 2007, we
recorded $0.2 million to research and development expense associated
with our professional diagnostic products business segment in
connection with these terminations. The total number of employees to be involuntarily
terminated under the plan is nine, of which six remain to be terminated as of September 30, 2007. As of
September 30, 2007, all costs remain unpaid. We do not expect to incur any additional costs related
to this plan.
In addition, we recorded restructuring charges associated with the formation of our joint
venture with The Procter & Gamble Company (P&G). See Note 14(a)(i) for additional information on
this plan.
(b) 2006 Restructuring Plans
In May 2006, we committed to a plan to cease operations at our manufacturing facility in San
Diego, California and to write off certain excess manufacturing equipment at other impacted
facilities. Additionally, in June 2006, we committed to a plan to reorganize the sales and
marketing and customer service functions in certain of our U.S. professional diagnostic companies.
For the nine months ended September 30, 2007, we recorded $0.4 million in net restructuring charges
under these plans, which primarily relates to $0.6 million in facility exit costs, offset by a $0.2
million adjustment due to the finalization of fixed asset write-offs. Of the $0.4 million net
charge, the $0.2 million adjustment was recorded to costs of sales, and was included in our
consumer diagnostic products segment, and $0.6 million was charged to general and administrative
expense, and was included in our professional diagnostic products business segment.
We recorded $1.2 million and $11.0 million, respectively, in restructuring charges during the
three and nine months ended September 30, 2006. The $1.2 million charge for the three months ended
September 30, 2006 related to severance charges. The $11.0 million charge for the nine months ended
September 30, 2006 included $1.9 million related to severance charges, $6.4 million related to
impairment charges on fixed assets and $2.7 million related to an impairment charge on an
intangible asset. The $11.0 million of charges for the nine months ended September 30, 2006
consisted of $7.6 million charged to cost of sales, $2.9 million charged to research and
development and $0.5 million charged to general and administrative expenses, of which $1.6 million,
$6.5 million and $2.9 million were included in our consumer diagnostic products, professional
diagnostic products and corporate and other business segments, respectively.
Including the charges recorded through September 30, 2007, we have incurred total
restructuring charges related to these plans of approximately $12.4 million. The total number of
employees to be involuntarily terminated under these plans is 131,
all of whom have been
terminated as of September 30, 2007. As of September 30, 2007, $0.1 million of the severance
related charges remains unpaid.
(c) 2005 Restructuring Plan
On May 9, 2005, we committed to a plan to cease operations at our facility in Galway, Ireland.
During the nine months ended September 30, 2006, we recorded a net restructuring gain of $3.2
million, of which $0.4 million related to charges for severance, early retirement and outplacement
services, $0.1 million related to an impairment charge of fixed assets, $0.6 million related to
facility closing costs and $4.3 million in foreign exchange gains as a result of recording a
cumulative translation adjustment to other income relating primarily to this plan of termination.
The charges for the nine months ended September 30, 2006 consisted of $0.7 million, charged to
cost of goods sold, $0.4 million charged to general and administrative and $4.3 million in gains
recorded to other expense. Of the $1.1
15
INVERNESS MEDICAL INNOVATIONS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Continued
(unaudited)
million included in operating income for the nine months
ended September 30, 2006, $0.9 million was included in our consumer diagnostic products business
segment and $0.2 million was included in our professional diagnostic products business segments.
Additionally, during the nine months ended September 30, 2006, we recorded a $1.4 million gain on
the sale of our CDIL facility in Ireland which has been recorded in loss on dispositions, net in
our consolidated statements of operations and is included in our corporate and other business
segment for this period.
(12) Other Arrangements
On February 25, 2005, we entered into a co-development agreement with ITI Scotland Limited
(ITI), whereby ITI agreed to provide us with approximately £30 million over three years to
partially fund research and development programs focused on identifying novel biomarkers and
near-patient and home use tests for cardiovascular and other diseases (the Programs). We agreed
to invest £37.5 million in the Programs over three years from the date of the agreement. Through
our subsidiary, Stirling Medical Innovations Limited (Stirling), we established a new research
center in Stirling, Scotland, where we consolidated many of our existing cardiology programs and
will ultimately commercialize products arising from the Programs. ITI and Stirling will have
exclusive rights to the developed technology in their respective fields of use. As of September 30,
2007, we had received approximately £27.5 million ($50.9 million) in funding from ITI. As qualified
expenditures are made under the co-development arrangement, we recognize the fee earned during the
period as a reduction of our related expenses, subject to certain limitations.
For the three and nine months ended September 30, 2007, we recognized $5.1 million and $14.9
million of reimbursements, respectively, of which $4.8 million and $13.7 million, respectively,
offset our research and development spending and $0.3 million and $1.2 million, respectively,
reduced our general, administrative and marketing spending incurred by Stirling.
For the three and nine months ended September 30, 2006, we recognized $4.7 million and $13.6
million of reimbursements, respectively, of which $4.3 million and $12.2 million, respectively,
offset our research and development spending and $0.4 million and $1.4 million, respectively,
reduced our general, administrative and marketing spending incurred by Stirling.
(13) In-Process Research and Development
In connection with two of our acquisitions since 2006, we have acquired various IPR&D
projects. Substantial additional research and development will be required prior to any of our
acquired IPR&D programs and technology platforms reaching technological feasibility. In addition,
once research is completed, each product candidate acquired will need to complete a series of
clinical trials and receive FDA or other regulatory approvals prior to commercialization. Our
current estimates of the time and investment required to develop these products and technologies
may change depending on the different applications that we may choose to pursue. We cannot give
assurances that these programs will ever reach technological feasibility or develop into products
that can be marketed profitably. In addition, we cannot guarantee that we will be able to develop
and commercialize products before our competitors develop and commercialize products for the same
indications. If products based on our acquired IPR&D programs and technology platforms do not
become commercially viable, our results of operations could be materially adversely affected.
The following table sets forth IPR&D projects for companies and certain assets we have
acquired since 2006 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discount Rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Used in |
|
|
Company/ |
|
|
|
|
|
|
|
|
|
|
|
Estimating |
|
|
Year Assets |
|
|
|
|
|
|
|
|
|
|
|
Cash |
|
Year of Expected |
Acquired |
|
Purchase Price |
|
|
IPR&D (1) |
|
|
Programs Acquired |
|
Flows(1) |
|
Launch |
|
Biosite/2007 |
|
$ |
1,800,000 |
|
|
$ |
13,000 |
|
|
Triage Sepsis Panel |
|
15% |
|
2008-2010 |
|
|
|
|
|
|
|
156,000 |
|
|
Triage NGAL |
|
15% |
|
2008-2010 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
169,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16
INVERNESS MEDICAL INNOVATIONS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Continued
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discount Rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Used in |
|
|
Company/ |
|
|
|
|
|
|
|
|
|
|
|
Estimating |
|
|
Year Assets |
|
|
|
|
|
|
|
|
|
|
|
Cash |
|
Year of Expected |
Acquired |
|
Purchase Price |
|
|
IPR&D (1) |
|
|
Programs Acquired |
|
Flows(1) |
|
Launch |
|
Clondiag/2006 |
|
$ |
24,000 |
|
|
$ |
1,800 |
|
|
CHF (Congestive Heart Failure) |
|
37% |
|
2008-2009 |
|
|
|
|
|
|
|
2,500 |
|
|
ACS (Acute Coronary Syndrome) |
|
37% |
|
2009-2010 |
|
|
|
|
|
|
|
660 |
|
|
HIV (Human Immuno-deficiency Virus) |
|
37% |
|
2008-2009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
4,960 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Management assumes responsibility for determining the valuation of the acquired IPR&D
projects. The fair value assigned to IPR&D for each acquisition is estimated by discounting,
to present value, the cash flows expected once the acquired projects have reached
technological feasibility. The cash flows are probability adjusted to reflect the risks of
advancement through the product approval process. In estimating the future cash flows, we also
considered the tangible and intangible assets required for successful exploitation of the
technology resulting from the purchased IPR&D projects and adjusted future cash flows for a
charge reflecting the contribution to value of these assets. |
(14) Investments in Unconsolidated Entities
(a) Equity Method Investments
(i) Joint Venture with The Procter & Gamble Company
On May 17, 2007, we completed our 50/50 joint venture with P&G for the development,
manufacturing, marketing and sale of existing and to-be-developed consumer diagnostic products,
outside the cardiology, diabetes and oral care fields. At the closing, we transferred our related
consumer diagnostic assets totaling $45.9 million, other than our manufacturing and core
intellectual property assets, to the joint venture, and P&G acquired its interest in the joint
venture for a cash payment of approximately $325.0 million.
In conjunction with the transfer of net assets to the joint venture, it was determined that
the working capital components of the closing balance sheet for the consumer diagnostic business
would be retained by us and, in lieu of these components, a note payable would be contributed by us
to the joint venture in the amount of $22.3 million. The note was payable in four installments, with
$2.0 million due at the date of note and three equal installments of $6.7 million each on the 30th,
60th and 90th day, respectively, following the date of the note. As of September 30, 2007, the note
had been repaid in full.
As part of the consummation of the joint venture, we entered into a shareholder agreement with
P&G, setting forth each partys rights and obligations with respect to the joint venture. The joint
venture is owned in equal parts by subsidiaries of our company and P&G (the Members). Each Member
has the right to appoint three managers to the Board of Managers. In general, a majority vote by
the Board of Managers is required to adopt or approve a business plan and budget; launch any new
product; issue or incur significant debt; incur significant expenditures not provided for in the
business plan and budget; file any material income or similar tax returns and reports; sublicense
or license any of the joint ventures intellectual property rights; appoint or dismiss any senior
officers of the joint venture; retain or otherwise appoint, or dismiss, the accountant and any
primary legal advisor or financial advisor to the joint venture; commence or settle any significant
litigation or arbitration; or market, or permit any distributor, commissionaire or sales agent to
market the joint venture products under a third partys label brand except for private label brands
in the ordinary course of business.
In certain circumstances, Members are required to make additional capital contributions on a
pro rata basis in accordance with membership interests in amounts sufficient to meet the funding
requirements of the joint venture pursuant to the business plan and budget and fund such other
working capital requirements, capital expenditures or other capital needs as may from time to time
be determined by action of the Members, including the capital expenditures required in connection
with the acquisition of any new business, and to fund any deficiency in the working capital or
capital expenditure requirements.
We also entered into an option agreement with P&G, pursuant to which P&G has the right, for a
period of 60 days commencing on the fourth anniversary date of the agreement, to require us to
acquire all of P&Gs interest in the joint venture at fair market value, and P&G has the right,
upon certain material breaches by us of our obligations to the joint venture, to acquire all of our
interest in the joint venture at fair market value. No gain on the proceeds
that we received from P&G through the formation of the joint venture will be recognized in our
financial statements until P&Gs option to require us to purchase its interest in the joint venture
expires. We have recorded the deferred gain of $302.5 million on our accompanying consolidated
balance sheet as of September 30, 2007.
17
INVERNESS MEDICAL INNOVATIONS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Continued
(unaudited)
We also entered into a manufacturing agreement with P&G, whereby we will manufacture consumer
diagnostic products and sell these products to the joint venture entity. In our capacity as the
manufacturer of products for the joint venture, we recorded $25.8 million and $40.1 million,
respectively, in manufacturing revenue for the three and nine months ended September 30, 2007 which
are included in net product sales on our accompanying consolidated statement of operations.
Furthermore, we entered into certain transition and long-term services agreements with the
joint venture, pursuant to which we will provide certain operational support services to the joint
venture. Revenue related to these service agreements amounted to $1.1 million and $1.7 million,
respectively, and are included in our net product sales on our consolidated statement of operations
for the three and nine months ended September 30, 2007, which is included in net product sales on
our accompanying consolidated statement of operations.
Upon completion of the arrangement to form the joint venture, we ceased to consolidate the
operating results of our consumer diagnostic products business related to the joint venture and
instead account for our 50% interest in the results of the joint venture under the equity method of
accounting in accordance with APB Opinion No. 18, The Equity Method of Accounting for Investments
in Common Stock. For the three and nine months ended September 30, 2007, we recorded $0.7 million
and $1.7 million, respectively, of earnings in equity earnings of unconsolidated entities, net of
tax, on our accompanying consolidated statement of operations, which represented our share of the
joint ventures net income for the period.
In connection with the joint venture, we committed to a plan to close one of our sales offices
in Germany, as well as evaluate redundancies in all departments of the consumer diagnostic products
business segment that are impacted by the formation of the joint venture. For the three and nine
months ended September 30, 2007, we recorded $0.4 million and $1.0 million, respectively, in
restructuring charges related to this plan, of which $0.6 million relates to severance costs and
$0.4 million relates to facility and other exit costs. Of the $1.0 million, $0.2 million was
charged to cost of sales, $0.1 million was charged to research and development expense, $0.4
million was charged to sales and marketing expense and $0.3 million was charged to general and
administrative expense. The total number of employees to be involuntarily terminated under this
plan is 17 of which 9 have been terminated as of September 30, 2007. Of the total $1.0 million in
severance and exit costs, $0.5 million remains unpaid as of September 30, 2007. We will continue to
evaluate the impact of the joint venture formation on our on-going consumer-related operations and
anticipate incurring additional charges related to this plan.
(ii) Vedalab S.A.
In November 2006, we acquired 40% of Vedalab S.A. (Vedalab), a French manufacturer and
supplier of rapid diagnostic tests in the professional markets. The aggregate purchase price was
$9.7 million which consisted of $7.6 million in cash, 49,787 shares of our common stock with an
aggregate fair value of $2.0 million and $0.1 million in estimated direct acquisition costs. On the
same date, we settled an ongoing patent infringement claim with Vedalab. Under the terms of the
settlement, Vedalab paid to us $5.1 million and agreed to pay royalties on future sales ranging
from 5% to 10%, depending on the products being sold in exchange for a license under certain
patents to manufacture its current products as its facility in Alencon, France. We account for our
40% investment in Vedalab under the equity method of accounting in accordance with APB Opinion No.
18. In January 2007, we received $0.7 million from Vedalab in the form of a dividend distribution.
This was accounted for as a reduction in the value of our investment in accordance with APB Opinion
No. 18. For the three and nine months ended September 30, 2007, we recorded $178,000 and $0.2
million, respectively, in equity earnings of unconsolidated entities in our accompanying
consolidated statement of operations, which represented our minority share of Vedalabs net income
for the respective period.
(iii) TechLab, Inc.
In May 2006, we acquired 49% of TechLab, Inc. (TechLab), a privately-held developer,
manufacturer and distributor of rapid non-invasive intestinal diagnostics tests in the areas of
intestinal inflammation, antibiotic associated diarrhea and parasitology. The aggregate purchase
price was $8.8 million which consisted of 303,417 shares of our common stock with an aggregate fair
value of $8.6 million and $0.2 million in estimated direct
18
INVERNESS MEDICAL INNOVATIONS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Continued
(unaudited)
acquisition costs. We account for our
49% investment in TechLab under the equity method of accounting, in accordance with APB Opinion No.
18. In August 2007, we received $0.6 million from TechLab in the form of a dividend distribution.
This was accounted for as a reduction in the value of our investment in accordance with APB Opinion
No. 18. For the three and nine months ended September 30, 2007, we recorded $0.2 million and $0.7
million, respectively, in equity earnings of unconsolidated entities, net of tax, in our
accompanying consolidated statement of operations, which represented our minority share of
TechLabs net income for the respective period.
(b) Investment in Chembio Diagnostics, Inc.
In September 2006, we acquired 5% of Chembio Diagnostics, Inc. (Chembio), a developer and
manufacturer of rapid diagnostic tests for infectious diseases, through the purchase of 40 shares
of their preferred stock. The preferred stock pays a dividend of 7%, payable in cash or common
stock. The aggregate purchase price of $2.0 million was paid in cash. In addition to the preferred
stock, we received a warrant to purchase 625,000 shares of Chembios common stock at $0.80 per
share. Chembios stock is publicly traded. The warrant, accounted for as a derivative instrument,
in accordance with SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities, had
a fair value of approximately $0.4 million at the date of issuance. The fair value of this warrant
was estimated at the time of issuance using the Black-Scholes pricing model and assuming no
dividend yield, expected volatility of 116%, risk-free rate of 4.9% and a contractual term of five
years. We mark to market the warrant over the contractual term and record the change through
unrealized gain in other income (expense), net on our accompanying consolidated statement of
operations. As of September 30, 2007 and December 31, 2006, the warrant was valued at $0.2 million
and $0.4 million, respectively.
(15) Marketable Securities
Marketable securities classified as current assets represent publicly-traded equity
investments which are classified as available-for-sale and recorded at fair value using the
specific identification method. Unrealized gains and losses (except for other than temporary
impairments) are recorded in other comprehensive income (loss), which is reported as a component of
stockholders equity.
During the period December 2006 through February 2007, we acquired an aggregate 750,000 shares
of Biosite common stock on the open market. Upon purchase, the shares were recorded at their market
value, as measured by their closing price on the Nasdaq Capital Market. We classified the
securities acquired through June 26, 2007 as non-current marketable securities in our accompanying
consolidated balance sheet as we intended to hold these securities indefinitely. With the June 2007
consummation of our Biosite acquisition, we included these shares, at their original cost, as part
of the purchase price.
(16) Pro Forma Financial Information
The following table presents selected unaudited financial information of our company,
including the assets of ACON laboratories business of researching, developing, manufacturing,
marketing and selling lateral flow immunoassay and directly-related products in the United States,
Canada, Europe (excluding Russia, the former Soviet Republics that are not part of the European
Union and Turkey), Israel, Australia, Japan and New Zealand (the Innovacon business), including
ABON BioPharm (Hangzhou) Co., Ltd (ABON), the owner of a newly-constructed manufacturing facility
in Hangzhou, China, Instant, Biosite and Cholestech, as if the acquisitions of these entities had
occurred on January 1, 2006. Pro forma results also reflect the impacts of the formation of the
joint venture for our consumer diagnostics business (Note 14(a)(i)) as if the joint venture had
been formed on January 1, 2006. Pro forma results exclude adjustments for various other less
significant acquisitions completed since January 1, 2006, as these acquisitions did not materially
affect our results of operations. The pro forma results are derived from the historical financial
results of the acquired businesses for all periods presented and are not necessarily indicative of
the results that would have occurred had the acquisitions been consummated on January 1, 2006.
19
INVERNESS MEDICAL INNOVATIONS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Continued
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
|
|
September 30, |
|
|
September 30, |
|
|
|
2007 |
|
|
2006 |
|
|
2007 |
|
|
2006 |
|
|
|
(in thousands, |
|
|
(in thousands, |
|
|
|
except per share amounts) |
|
|
except per share amounts) |
|
Pro forma net revenue |
|
$ |
249,429 |
|
|
$ |
219,521 |
|
|
$ |
722,001 |
|
|
$ |
656,410 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro forma net loss |
|
$ |
(7,626 |
) |
|
$ |
(29,564 |
) |
|
$ |
(25,576 |
) |
|
$ |
(345,573 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro forma net loss
per common share
basic and diluted
(1) |
|
$ |
(0.14 |
) |
|
$ |
(0.69 |
) |
|
$ |
(0.52 |
) |
|
$ |
(8.43 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Net loss per common share amounts are computed as described in Note 6. |
(17) Senior Credit Facilities
As of December 31, 2006, $44.8 million of borrowings were outstanding under our then senior
credit facility (the Prior Credit Agreement). On February 1, 2007, using a portion of the
proceeds from our sale of 6.9 million shares of common stock in the first quarter of 2007 (Note 9),
we paid the remaining principal balance outstanding and accrued interest under the Prior Credit
Agreement. We terminated our Prior Credit Agreement in conjunction with our refinancing activities
discussed below.
For the nine months ended September 30, 2007, interest expense, including amortization of
deferred financing costs, under this senior credit facility was $4.7 million. Included in interest
expense for the nine months ended September 30, 2007, is the write-off of $2.6 million, in
unamortized deferred financing costs. For the three and nine months ended September 30, 2006, we
recorded interest expense, including amortization of deferred financing costs, under this senior
credit facility in the aggregate amount of $2.7 million and $6.9 million, respectively. We had no
outstanding loans under the Prior Credit Agreement at the time it was terminated.
On June 26, 2007, in connection with our acquisition of Biosite, we entered into a secured
First Lien Credit Agreement and a secured Second Lien Credit Agreement (collectively, the Credit
Agreements) with certain lenders, General Electric Capital Corporation as administrative agent and
collateral agent, and certain other agents and arrangers, and certain related guaranty and security
agreements. The First Lien Credit Agreement provides for term loans in the aggregate amount of
$900.0 million and, subject to our continued compliance with the First Lien Credit Agreement, a
$150.0 million revolving line of credit. The Second Lien Credit Agreement provides for term loans
in the aggregate amount of $250.0 million. As of September 30, 2007, aggregate borrowings amounted
to $41.0 million under the revolving line of credit and $1.1 billion under the term loans. Interest
expense related to our new credit facility which included the term loans and revolving line of
credit for the three and nine months ended September 30, 2007, including amortized deferred
financing costs, was $27.5 million and $29.2 million, respectively. As of September 30, 2007, we
were in compliance with all debt covenants related to the above debt.
In
August 2007, we entered into interest rate swap contracts, with
an effective date of September 28, 2007, that have a total notional value
of $350.0 million and have a maturity date of September 28, 2010. These interest rate swap
contracts will pay us variable interest at the three-month LIBOR rate, and we will pay the
counterparties a fixed rate of 4.85%. These interest rate swap contracts were entered into to
convert $350.0 million of the $1.3 billion variable rate term loan under the senior credit facility
into fixed rate debt. Based on the terms of the interest rate swap contracts and the underlying
debt, these interest rate swap contracts were determined to be effective, and thus qualify as a
cash flow hedge under SFAS No. 133. As such, any changes in the fair value of these interest rate swaps are recorded
in other comprehensive income on the accompanying consolidated balance sheet until earnings are
affected by the variability of cash flows.
In addition, on June 26, 2007, we also fully repaid our 8.75% senior subordinated notes due
2012 (the Notes). The total amount repaid, including principal of $150.0 million and a prepayment
premium of $9.3 million, was $159.3 million. Accrued interest of $4.8 million was also paid as part
of the final settlement of these Notes and unamortized deferred financing costs of $3.7 million
were written off as a result of the repayment.
Additionally, we received proceeds from the May 14, 2007 sale of $150.0 million principal
amount of 3% convertible senior subordinated notes due 2016 (the Convertible Notes) in a private
placement to qualified institutional buyers. At the initial conversion price of $52.30, the
Convertible Notes are convertible into an
20
INVERNESS MEDICAL INNOVATIONS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Continued
(unaudited)
aggregate 2,868,120 shares of our common stock. The
conversion price is subject to adjustment one year from the date of sale if the 30 day
volume-weighted average trading price of our common stock as of such date is lower than $40.23,
subject to a floor of $40.23, or from time to time in the event of stock splits, stock dividends,
recapitalizations and other similar events. The conversion price is also subject to a make-whole
payment in the form of an adjustment to the conversion price in the event of a fundamental change
(as defined in the Indenture). Interest accrues at 3% per annum, compounded daily, on the
outstanding principal amount and is payable in arrears on May 15th and Nov 15th, which will start
on November 15, 2007. Interest expense for the three and nine months ended September 30, 2007,
including amortized deferred costs, was $1.2 million and $1.8 million, respectively.
We evaluated the Convertible Notes agreement for potential embedded derivatives under SFAS No.
133 and related applicable accounting literature, including EITF Issue No. 00-19, Accounting for
Derivative Financial Instruments Indexed to, and Potentially Settled in, a Companys Own Stock,
and EITF Issue No. 05-4, The Effect of a Liquidated Damages Clause on a Freestanding Financial
Instrument Subject to Issue No. 00-19. The conversion feature and the make-whole payment were
determined to not meet the embedded derivative criteria as set forth by SFAS No. 133. Therefore, no
fair value has been recorded for these items.
(18) Defined Benefit Pension Plan
Our subsidiary in England, Unipath Ltd., has a frozen defined benefit pension plan established
for certain of its employees. The net periodic benefit costs are as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2007 |
|
|
2006 |
|
|
2007 |
|
|
2006 |
|
Service cost |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
Interest cost |
|
|
155 |
|
|
|
144 |
|
|
|
458 |
|
|
|
420 |
|
Expected return on plan assets |
|
|
(129 |
) |
|
|
(120 |
) |
|
|
(381 |
) |
|
|
(349 |
) |
Realized losses |
|
|
89 |
|
|
|
83 |
|
|
|
262 |
|
|
|
240 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net periodic benefit cost |
|
$ |
115 |
|
|
$ |
107 |
|
|
$ |
339 |
|
|
$ |
311 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(19) Financial Information by Segment
Under SFAS No. 131, Disclosures about Segments of an Enterprise and Related Information,
operating segments are defined as components of an enterprise about which separate financial
information is available that is evaluated regularly by the chief operating decision-maker, or
decision making group, in deciding how to allocate resources and in assessing performance. Our
chief operating decision-making group is composed of the chief executive officer and members of
senior management. Our reportable operating segments are Consumer Diagnostic Products, Vitamins and
Nutritional Supplements, Professional Diagnostic Products, and Corporate and Other. Our operating
results include license and royalty revenue which are allocated to Consumer Diagnostic Products and
Professional Diagnostic Products on the basis of the original license or royalty agreement.
Included in the operating income of Professional Diagnostic Products are expenses related to our
research and development activities in the area of cardiology for the three and nine months ended
September 30, 2007, the latter of which amounted to $8.6 million, net of the ITI funding (Note 12)
of $4.8 million, and $18.4 million, net of the ITI funding of $13.7 million, respectively. $9.9
million, net of the ITI funding of $4.3 million and $22.1 million, net of $12.2 million of the ITI
funding, respectively, for the three and nine months ended September 30, 2006, respectively, and
have been included in Corporate and Other. Operating loss of $178.1 million and $234.8 million, for the three and nine months ended
September 30, 2007, respectively, in our Corporate and Other segment includes the write-off of
$169.0 million of IPR&D incurred in our acquisition of Biosite and for the nine months ended
September 30, 2007, $45.2 million of stock-based compensation related to employee stock options
assumed in the acquisition of Biosite. Total assets related to our cardiology research operations in Scotland and Germany, which are
included in Professional Diagnostic Products in 2007 and included in Corporate and Other in 2006 in the tables below, amounted to $37.7 million at
September 30, 2007 and $18.4 million at December 31, 2006.
We evaluate performance of our operating segments based on revenue and operating income
(loss). Segment information for the three and nine months ended September 30, 2007 and 2006 is as
follows (in thousands):
21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer |
|
|
Vitamins and |
|
|
Professional |
|
|
Corporate |
|
|
|
|
|
|
Diagnostic |
|
|
Nutritional |
|
|
Diagnostic |
|
|
and |
|
|
|
|
|
|
Products |
|
|
Supplements |
|
|
Products |
|
|
Other |
|
|
Total |
|
Three Months Ended September 30,
2007: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue to external customers |
|
$ |
33,263 |
|
|
$ |
20,710 |
|
|
$ |
183,663 |
|
|
$ |
|
|
|
$ |
237,636 |
|
Operating income (loss) |
|
$ |
3,600 |
|
|
$ |
607 |
|
|
$ |
17,421 |
|
|
$ |
(178,103 |
) |
|
$ |
(156,475 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30,
2006: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue to external customers |
|
$ |
45,350 |
|
|
$ |
18,462 |
|
|
$ |
81,100 |
|
|
$ |
|
|
|
$ |
144,912 |
|
Operating income (loss) |
|
$ |
6,373 |
|
|
$ |
(1,174 |
) |
|
$ |
11,941 |
|
|
$ |
(16,096 |
) |
|
$ |
1,044 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, 2007: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue to external customers |
|
$ |
131,148 |
|
|
$ |
53,643 |
|
|
$ |
366,789 |
|
|
$ |
|
|
|
$ |
551,580 |
|
Operating income (loss) |
|
$ |
16,098 |
|
|
$ |
(2,094 |
) |
|
$ |
38,119 |
|
|
$ |
(234,804 |
) |
|
$ |
(182,681 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, 2006: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue to external customers |
|
$ |
134,196 |
|
|
$ |
59,559 |
|
|
$ |
218,691 |
|
|
$ |
|
|
|
$ |
412,446 |
|
Operating income (loss) |
|
$ |
23,234 |
|
|
$ |
(2,223 |
) |
|
$ |
22,494 |
|
|
$ |
(45,654 |
) |
|
$ |
(2,149 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of September 30, 2007 |
|
$ |
309,841 |
|
|
$ |
49,216 |
|
|
$ |
3,048,151 |
|
|
$ |
84,333 |
|
|
$ |
3,491,541 |
|
As of December 31, 2006 |
|
$ |
314,815 |
|
|
$ |
49,896 |
|
|
$ |
625,560 |
|
|
$ |
95,500 |
|
|
$ |
1,085,771 |
|
(20) Related Party Transaction
On March 22, 2007, we entered into a convertible loan agreement with a related party whereby
we loaned the related party £7.5 million ($14.7 million as of the transaction date). Under the
terms of the agreement, the loan amount would simultaneously convert into shares of the related
partys common stock per the prescribed conversion formula defined in the loan agreement, in the
event the related party consummated a specific target acquisition on or before September 30, 2007.
On May 15, 2007, the related party consummated a specific target acquisition and the loan converted
into 5,208,333 shares of the related partys common stock which is included in investments in
unconsolidated entities on our accompanying consolidated balance sheet at September 30, 2007.
(21) Material Contingencies and Legal Settlements
Due to the nature of our business, we may from time to time be subject to commercial disputes,
consumer product claims or various other lawsuits arising in the ordinary course of our business,
and we expect this will continue to be the case in the future. These lawsuits generally seek
damages, sometimes in substantial amounts, for commercial or personal injuries allegedly suffered
and can include claims for punitive or other special damages. In addition, we aggressively defend
our patent and other intellectual property rights. This often involves bringing infringement or
other commercial claims against third parties, which can be expensive and can results in
counterclaims against us. We are currently not a party to any material legal proceedings.
As of September 30, 2007, we had contingent consideration obligations related to our
acquisitions of Spectral/Source, Instant, First Check, Binax, Inc. (Binax) and CLONDIAG chip
technologies Gmbh (Clondiag). The contingent considerations will be accounted for as increases in
the aggregate purchase prices if and when the contingencies occur.
With respect to Spectral/Source, we will pay an earn-out equal to two times the consolidated
revenue of Spectral/Source less $4.0 million, if the consolidated profits before tax of
Spectral/Source is at least $0.9 million on the one year anniversary (milestone period) following
the acquisition date. If consolidated profits before tax of Spectral/Source for the milestone
period are less than $0.9 million, then the amount of the payment will be equal to
seven times Spectral/Sources consolidated profits before tax less $4.0 million. The
contingent consideration is payable 60% in cash and 40% in stock.
With respect to Instant, the terms of the acquisition agreement provide for $16.6 million of
contingent consideration payable in cash or cash and stock to acquire the remaining 25% ownership
interest in Instant. The
22
INVERNESS MEDICAL INNOVATIONS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Continued
(unaudited)
seller has the option, but is not obligated, to sell his remaining 25%
during the four-year period commencing April 1, 2008 and ending March 31, 2012. The option is
contingent upon the business meeting certain revenue and gross profit targets. The option shall
terminate if not exercised during the period mentioned above. Furthermore, we have the option, but
not an obligation, to acquire the remaining 25% from the seller on or before March 31, 2012 for
$24.6 million in cash or cash and stock. If the seller is not an employee of the company at the
time of exercise, the full consideration will be payable in cash. The option will terminate if not
exercised during the period mentioned above.
With respect to First Check, we will pay an earn-out to First Check equal to the incremental
revenue growth of the acquired products for 2007 and for the first nine months of 2008, as compared
to the immediately preceding comparable periods.
With respect to Binax, the terms of the acquisition agreement provide for $11.0 million of
contingent cash consideration payable to the Binax shareholders upon the successful completion of
certain new product developments during the five years following the acquisition. During the three
months ended September 30, 2007, we paid and recorded $3.7 million related to the successful
development of one of the qualifying products.
With respect to Clondiag, the terms of the acquisition agreement provide for $8.9 million of
contingent consideration, consisting of 224,316 shares of our common stock and approximately $3.0
million of cash or stock in the event that four specified products are developed on Clondiags
platform technology during the three years following the acquisition date.
(22) Recent Accounting Pronouncements
Recently Issued Standards
In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements. SFAS No. 157
establishes a framework for measuring fair value in generally accepted accounting principles, and
expands disclosures about fair value measurements. The standard applies whenever other standards
require (or permit) assets or liabilities to be measured at fair value. The standard does not
expand the use of fair value in any new circumstances. SFAS No. 157 is effective for financial
statements issued for fiscal years beginning after November 15, 2007, and interim periods within
those fiscal years. Earlier application is encouraged. We continue to evaluate the impact that the
adoption of SFAS No. 157 will have, if any, on our consolidated financial statements.
In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and
Financial Liabilities Including an Amendment of FASB No 115. This Statement provides companies
with an option to measure, at specified election dates, many financial instruments and certain
other items at fair value that are not currently measured at fair value. The standard also
establishes presentation and disclosure requirements designed to facilitate comparison between
entities that choose different measurement attributes for similar types of assets and liabilities.
If the fair value option is elected, the effect of the first remeasurement to fair value is
reported as a cumulative effect adjustment to the opening balance of retained earnings. The
statement is to be applied prospectively upon adoption. SFAS No. 159 is effective for fiscal years
beginning after November 15, 2007. We plan to adopt SFAS No. 159 as of January 1, 2008, and are
currently evaluating the impact of SFAS No. 159 on our results of operations or financial position.
In June 2007, the EITF reached a consensus on EITF Issue No. 07-03, Accounting for
Nonrefundable Advance Payments for Goods or Services to Be Used in Future Research and Development
Activities. EITF 07-03 concludes that non-refundable advance payments for future research and
development activities should be deferred and capitalized until the goods have been delivered or
the related services have been performed. If an entity does not expect the goods to be delivered or
services to be rendered, the capitalized advance payment should be charged to
expense. This consensus is effective for financial statements issued for fiscal years
beginning after December 15, 2007, and interim periods within those fiscal years. Earlier adoption
is not permitted. The effect of applying the consensus will be prospective for new contracts
entered into on or after that date. We do not believe that adoption of the consensus in the first
quarter of 2008 will have a material impact on our consolidated financial statements.
23
INVERNESS MEDICAL INNOVATIONS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Continued
(unaudited)
Recently Adopted Standards
We adopted FIN 48, Accounting for Uncertainty in Income Taxes an Interpretation of FASB
Statement 109 on January 1, 2007. FIN 48 clarifies the accounting and reporting for uncertainties
in income tax law. This Interpretation prescribes a comprehensive model for the financial statement
recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected
to be taken in income tax returns. See Note 7 for information pertaining to the effects of adoption
on our consolidated balance sheet.
In February 2006, the FASB issued SFAS No. 155, Accounting for Certain Hybrid Financial
Instruments, which amends SFAS No. 133, Accounting for Derivative Instruments and Hedging
Activities and SFAS No. 140, Accounting for Transfers and Servicing of Financial Assets and
Extinguishments of Liabilities. SFAS No. 155 simplifies the accounting for certain derivatives
embedded in other financial instruments by allowing them to be accounted for as a whole if the
holder elects to account for the whole instrument on a fair value basis. SFAS No. 155 also
clarifies and amends certain other provisions of SFAS No. 133 and SFAS No. 140. SFAS No. 155 is
effective for all financial instruments acquired, issued or subject to a remeasurement event
occurring in fiscal years beginning after September 15, 2006. The adoption of SFAS No. 155 did not
have any impact on our financial position, results of operations or cash flows.
In June 2006, the FASB ratified the consensus on EITF Issue No. 06-03, How Taxes Collected
from Customers and Remitted to Governmental Authorities Should Be Presented in the Income
Statement. The scope of EITF Issue No. 06-03 includes any tax assessed by a governmental authority
that is directly imposed on a revenue-producing transaction between a seller and a customer and may
include, but is not limited to, sales, use, value added, Universal Service Fund (USF)
contributions and some excise taxes. The Task Force affirmed its conclusion that entities should
present these taxes in the income statement on either a gross or a net basis, based on their
accounting policy, which should be disclosed pursuant to APB Opinion No. 22, Disclosure of
Accounting Policies. If such taxes are significant, and are presented on a gross basis, the amounts
of those taxes should be disclosed. The consensus on EITF Issue No. 06-03 is effective for interim
and annual reporting periods beginning after December 15, 2006. As required by EITF Issue 06-03, we
adopted this new accounting standard for the interim period beginning January 1, 2007. The adoption
of EITF Issue 06-03 did not have any impact on our financial position, results of operations or
cash flows.
In December 2006, the FASB issued FASB Staff Position (FSP) No. EITF 00-19-2, Accounting for
Registration Payment Arrangements. This FSP specifies that the contingent obligation to make future
payments or otherwise transfer consideration under a registration payment arrangement, whether
issued as a separate agreement or included as a provision of a financial instrument or other
agreement, should be separately recognized and measured in accordance with FASB Statement No. 5,
Accounting for Contingencies. The guidance in this FSP amends FASB Statement No. 133, and No. 150,
Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity
and FIN 45, Guarantors Accounting and Disclosure Requirements for Guarantees, Including Indirect
Guarantees of Indebtedness of Others to include scope exceptions for registration payment
arrangements. This FSP is effective immediately for registration payment arrangements and the
financial instruments subject to those arrangements that are entered into or modified subsequent to
the date of issuance of this FSP. For registration payment arrangements and financial instruments
subject to those arrangements that were entered into prior to the issuance of this FSP, this
guidance is effective for financial statements issued for fiscal years beginning after December 15,
2006, and interim periods within those fiscal years. As required by EITF 00-19-2, we adopted this
new accounting standard on January 1, 2007. The adoption of EITF 00-19-2 did not have any impact on
our financial position, results of operations or cash flows.
(23) Guarantor Financial Information
On June 26, 2007, we fully repaid our $150.0 million in senior subordinated notes which we
previously issued to qualified institutional buyers in reliance on Rule 144A under the Securities
Act of 1933, as amended (the Securities Act), and outside the United States in compliance with
Regulation S of the Securities Act. Our payment obligations under the bonds were guaranteed by all
of our domestic subsidiaries. As a result of our payment in full, guarantor financial information
is no longer required.
24
ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Financial Overview
We are a global leader in rapid point-of-care diagnostic products. Through our professional
diagnostic products segment, we develop, manufacture and market an extensive array of innovative
rapid diagnostic test products and other in vitro diagnostic tests to medical professionals and
laboratories for detection of infectious diseases, cardiac conditions, drugs of abuse and
pregnancy. Our professional products are sold in approximately 90 countries through a direct sales
force and an extensive network of independent global distributors. Our consumer diagnostic products
segment consists primarily of manufacturing operations related to our role as the exclusive
manufacturer of products for SPD Swiss Precision Diagnostics (Swiss Precision), our 50/50 joint
venture with The Procter & Gamble Company (P&G). Swiss Precision holds a leadership position in
the worldwide over-the-counter pregnancy and fertility/ovulation test market. We also manufacture
and market a variety of vitamins and nutritional supplements under our other brands and those of
private label retailers primarily in the U.S. consumer market.
We have grown our businesses by leveraging our strong intellectual property portfolio and
making selected strategic acquisitions. We plan to continue to pursue selective acquisitions,
particularly acquisitions that would increase the market penetration and breadth of our product
offerings and expand our distribution capabilities. We may incur
additional indebtedness in connection with those acquisitions. We are also focused on improving our margins
through consolidation of certain of our manufacturing operations at lower costs facilities. Our
acquisition of the Innovacon business represents a key component of this strategy. During 2007, we
are seeing improved margins on some of our existing products as we move production of certain
products from higher costs facilities to our ABON facility in
Hangzhou, China.
Our 50/50 joint venture with P&G, consummated during the second quarter of 2007, continues to
expand the reach of our over-the-counter diagnostic products, while enabling enhanced focus on our
rapidly growing professional diagnostic products segment and, in particular, on our cardiology
development programs. Our acquisition of Biosite, Inc. (Biosite), during the second quarter of
2007 has also expanded our product offerings and research capabilities, particularly in the area of
cardiology diagnostics.
During the third quarter of 2007, we completed several acquisitions, including that of
Cholestech Corporation (Cholestech), which together provide us the unique ability to assess
cardiac risk, diagnose cardiac conditions and potentially monitor the condition and response to
therapy of cardiac patients. The Cholestech acquisition was consummated pursuant to a merger
agreement on September 12, 2007.
On October 18, 2007, we announced the implementation of several plans to restructure and
integrate our U.S. sales, marketing, order management and fulfillment operations. The objectives of
the plans are to eliminate redundant costs resulting from acquisitions, including our recent
acquisitions of Biosite and Cholestech, and to improve customer responsiveness and efficiencies in
operations. We additionally announced our plan to transition to a shared service center model in
North America. We anticipate significant cost savings to our businesses as a result of these plans.
We continue to emphasize new product development. This requires substantial investment and
involves significant inherent risk. We intend to continue to devote substantial resources to
research and development activities. We also continue to aggressively defend our substantial
intellectual property portfolios, which underlie our emphasis on new product development, against
potential infringers.
For the three and nine months ended September 30, 2007, we recorded net revenue of $237.6
million and $551.6 million, respectively, compared to $144.9 million and $412.4 million,
respectively for the three and nine months ended September 30, 2006. The revenue increase was
primarily due to increased sales in our professional diagnostic products segment, contributed by
businesses acquired which contributed $94.3 million of the increased product revenue. Adjusted for
the favorable impact of currency translation, net revenue of
$235.7 million for the three months ended September 30,
2007 was approximately 63% higher than for the three months ended
September 30, 2006 and net revenue of $543.4
million for the nine months ended September 30, 2007 was approximately 32% higher than for the
comparable nine months ended September 30, 2006. Our reported consumer diagnostic products segment net revenue
for the three months ended September 30, 2007 was adversely impacted as a result of the May 17,
2007 formation of our joint venture with P&G, as we no longer
consolidate the results of this portion
of our business beginning on May 18, 2007, but account for our 50% interest under the equity method
of accounting. Accordingly, after May 17, 2007, the results from our ownership interest in the
joint venture are reported on our accompanying consolidated statements of operations in
25
equity earnings of unconsolidated entities for the three and nine months ended September 30,
2007. During the three and nine months ended September 30, 2007, we reported $0.7 million and $1.7
million, respectively, in equity earnings, net of tax, related to this joint venture. Our vitamins
and nutritional supplements business segment experienced a 12% increase in net product revenue for
the three months ending September 30, 2007, compared to the comparable period in 2006, and a 10%
decrease in net product revenue for the first nine months of 2007, compared to the first nine
months of 2006.
For the three and nine months ended September 30, 2007, we incurred a net loss of $180.6
million and $229.0 million, respectively, compared to a net loss of $9.7 million and $22.9 million,
respectively, for the three and nine months ended September 30, 2006. The net loss in both of the
2007 periods are primarily attributed to a $169.0 million write-off of in-process research and
development projects at Biosite based on appraised values. The nine month loss in 2007 also
included a $45.2 million stock-based compensation charge associated with the acceleration and
conversion of employee stock options in conjunction with our acquisition of Biosite and a write-off
of $15.4 million of deferred financing costs and prepayment penalty related to the repayment of our
outstanding debt in conjunction with our financial arrangements related to our Biosite acquisition.
Recent Developments
On August 6, 2007, we entered into a merger agreement to acquire HemoSense, Inc.
(HemoSense), a point-of-care diagnostic healthcare company that manufactures and sells
easy-to-use, handheld blood coagulation systems for monitoring patients taking warfarin, in a stock
for stock merger at a fixed exchange ratio of 0.274192 shares of our common stock for each share of
common stock of HemoSense. Based on this exchange ratio, we issued approximately
3,691,387 shares of our common stock to the
HemoSense shareholders, and reserved approximately 655,242 shares of our common stock for future
issuance upon the exercise of assumed options and warrants. The
merger was completed on November 6, 2007. The transaction was structured as a tax-free reorganization.
On October 24, 2007, we entered into an agreement to acquire Alere Medical, Inc. (Alere), a
leading provider of health and care management services helping patients with chronic illnesses
manage their conditions through a unique combination of at-home monitoring, patient education and
nurse-patient relationships. The purchase price is $302.0 million, comprising approximately $125.0
million in cash and $177.0 million in our common stock. The transaction is expected to close prior
to the end of the calendar year, subject to satisfaction of regulatory and other customary closing
conditions.
Results of Operations
Net Product Sales, Total and by Business Segment. Total net product sales increased by $87.7
million, or 62%, to $228.6 million for the three months ended September 30, 2007 from $140.9
million for the three months ended September 30, 2006. Excluding the favorable impact of currency
translation, net product sales for the three months ended
September 30, 2007 increased by $85.7
million, compared to the three months ended September 30, 2006. Total net product sales increased
by $134.3 million, or 34%, to $534.5 million for the nine months ended September 30, 2007 from
$400.2 million for the nine months ended September 30, 2006. Excluding the favorable impact of
currency translation, net product sales for the nine months ended September 30, 2007 increased by
$126.1 million, compared to the nine months ended September 30, 2006. Net product sales by business
segment for the three and nine months ended September 30, 2007 and 2006 are as follows (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
|
|
|
Nine Months Ended |
|
|
|
|
|
|
September 30, |
|
|
% |
|
September 30, |
|
|
% |
|
|
2007 |
|
|
2006 |
|
|
Change |
|
2007 |
|
|
2006 |
|
|
Change |
Consumer diagnostic products |
|
$ |
30,330 |
|
|
$ |
43,885 |
|
|
|
(31 |
)% |
|
$ |
126,397 |
|
|
$ |
129,427 |
|
|
|
(2 |
)% |
Vitamins and nutritional supplements |
|
|
20,710 |
|
|
|
18,462 |
|
|
|
12 |
% |
|
|
53,643 |
|
|
|
59,559 |
|
|
|
(10 |
)% |
Professional diagnostic products |
|
|
177,528 |
|
|
|
78,549 |
|
|
|
126 |
% |
|
|
354,481 |
|
|
|
211,260 |
|
|
|
68 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total net product sales |
|
$ |
228,568 |
|
|
$ |
140,896 |
|
|
|
62 |
% |
|
$ |
534,521 |
|
|
$ |
400,246 |
|
|
|
34 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26
Consumer Diagnostic Products
Net product sales
of our consumer diagnostic products decreased by $13.6 million, or 31%,
comparing the three months ended September 30, 2007 to the three months ended September 30, 2006.
Net product sales of our consumer diagnostic products decreased by $3.0 million, or 2%, comparing
the nine months ended September 30, 2007 to the nine months ended September 30, 2006. Excluding the
favorable impact from currency translation, net product sales of our consumer diagnostic products
decreased by $14.4 million, or 33%, and decreased $7.8 million, or 6%, respectively, comparing the
three and nine months ended September 30, 2007 with the three and nine months ended September 30,
2006. The May 17, 2007 formation of our 50/50 joint venture (Swiss Precision) with P&G impacted our
reported results for our consumer diagnostic products, as we account for the results of the joint
venture under the equity method of accounting and, as of May 17, 2007, no longer consolidate the
results for this portion of our business in our consumer diagnostic products segment. Net product
sales of our consumer diagnostic products for the three and nine months ended September 30, 2007
does however include $25.8 million and $40.1 million, respectively, of manufacturing revenue
associated with our manufacturing agreement with Swiss Precision, whereby we manufacture and sell
consumer diagnostic products to the joint venture. Our recent acquisition of First Check in January
2007 contributed $3.5 million and $9.2 million, respectively, in net product sales during the three
and nine months ended September 30, 2007 associated with sales of over-the-counter drugs of abuse
products.
Vitamins and Nutritional Supplements
Our vitamins and nutritional supplements net product sales increased by $2.2 million, or 12%,
comparing the three months ended September 30, 2007 to the three months ended September 30, 2006
and decreased by $5.9 million, or 10%, comparing the nine months ended September 30, 2007 to the
nine months ended September 30, 2006. The increase in the comparative three-month period is largely
attributed to a partial recovery in our private label business which was impacted as a result of
several large customers reducing their inventory levels in prior quarters. The decrease in the
comparative nine-month period is reflective of continuing competitive pressures, particularly in
our private label business.
Professional Diagnostic Products
Net product sales of our professional diagnostic products increased by $99.0 million, or 126%,
comparing the three months ended September 30, 2007 to the three months ended September 30, 2006.
Excluding the favorable impact from currency translation, net product sales of our professional
diagnostic products increased by $97.9 million, or 125%, comparing the three months ended September
30, 2007 to the three months ended September 30, 2006. Of the currency adjusted increase, net
product sales increased as a result of our acquisitions of: (i) Biosite in June 2007, which
contributed $77.2 million, (ii) Cholestech in September 2007, which contributed $6.6 million, (iii)
QAS in June 2007, which contributed $5.3 million, and (iv) various less significant acquisitions,
which contributed an aggregate of $5.1 million. Organic growth of approximately 5% also contributed
to the increase, as a result of growth in our clinical product sales and as we continued to gain
market share particularly with our highly differentiated, higher margin brands and our private
label offerings.
Net product sales of our professional diagnostic products increased by $143.2 million, or 68%,
comparing the nine months ended September 30, 2007 to the nine months ended September 30, 2006.
Excluding the favorable impact from currency translation, net product sales of our professional
diagnostic products increased by $139.8 million, or 66%, comparing the nine months ended September
30, 2007 to the nine months ended September 30, 2006. Of the currency adjusted increase, net
product sales increased as a result of our acquisitions of: (i) Biosite in June 2007, which
contributed $85.2 million, (ii) QAS in June 2007, which contributed $6.7 million, (iii) Cholestech
in September 2007, which contributed $6.6 million, (iv) Instant in March 2007, which contributed
$6.3 million, (v) the Innovacon business in March 2006, which contributed $10.3 million and (vi)
various less significant acquisitions, which contributed an aggregate of $12.5 million. Organic
growth of approximately 6% also contributed to the increase during the nine-month period, as a
result of growth in our clinical product sales and as we continued to gain market share
particularly with our highly differentiated, higher margin brands and our private label offerings.
License and Royalty Revenue. License and royalty revenue represents license and royalty fees
from intellectual property license agreements with third parties. License and royalty revenue
increased by approximately $5.1 million, or 126%, to $9.1 million for the three months ended
September 30, 2007 from $4.0 million for the three months
27
ended September 30, 2006 and increased by approximately $4.9 million, or 40%, to $17.1 million
for the nine months ended September 30, 2007 from $12.2 million for the nine months ended September
30, 2006. The increase for the comparative three and nine-month periods reflects $2.8 million of
incremental royalty revenue contributed by Biosite, which was acquired in June 2007. Additionally,
incremental royalty revenue was derived from new royalty agreements entered into during 2007, along
with increases associated with certain existing royalty agreements, partially offset by decreases
in other royalty arrangements.
Gross Profit and Margin. Gross profit increased by $49.2 million, or 80%, to $110.3 million
for the three months ended September 30, 2007 from $61.1 million for the three months ended
September 30, 2006. Gross profit during the three months ended September 30, 2007 benefited
primarily from higher than average margins earned on revenue from our recently acquired businesses,
as discussed above, and higher margins achieved as a result of our lower manufacturing costs
associated with our China facility. Included in cost of sales for the three months ended September
30, 2007 was a $6.3 million charge related to the write-up to fair market value of inventory
acquired in connection with our acquisitions of Biosite and Cholestech. Included in cost of sales
for the three months ended September 30, 2006 is a $1.2 million restructuring charge related to the
closure of our ABI operation in San Diego, California, along with the write-off of fixed assets at
other facilities impacted by restructuring plans.
Gross profit increased by $93.1 million, or 57%, to $255.0 million for the nine months ended
September 30, 2007 from $161.9 million for the nine months ended September 30, 2006. Gross profit
during the nine months ended September 30, 2007 benefited primarily from higher than average
margins earned on revenue from our recently acquired businesses, as discussed above, and higher
margins achieved as a result of our lower manufacturing costs associated with our China facility.
Included in cost of sales for the nine months ended September 30, 2007 was a $7.5 million charge
related to the Biosite and Cholestech acquisitions mentioned above. Cost of sales for the nine
months ended September 30, 2006 included $8.3 million in restructuring charges related to the
closure of our Galway, Ireland manufacturing facility and our Applied Biotech, Inc. (ABI) operation in San Diego,
California, along with the write-off of fixed assets at other facilities impacted by restructuring
plans.
Cost of sales included intangible amortization expense of $7.5 million and $3.2 million for
the three months ended September 30, 2007 and 2006, respectively, and $13.8 million and $8.5
million for the nine months ended September 30, 2007 and 2006, respectively.
Overall gross margin was 46% and 46% for the three and nine months ended September 30, 2007,
respectively, compared to 42% and 39% for the three and nine months ended September 30, 2006,
respectively.
Gross Profit from Net Product Sales by Business Segment. Gross profit from net product sales
represents total gross profit less gross profit associated with license and royalty revenue. Gross
profit from total net product sales increased by $44.9 million, or 77%, to $103.4 million for the
three months ended September 30, 2007 from $58.5 million for the three months ended September 30,
2006. Gross profit from total net product sales increased by $91.7 million, or 60%, to $245.4
million for the nine months ended September 30, 2007 from $153.7 million for the nine months ended
September 30, 2006. Gross profit from net product sales by business segment for the three and nine
months ended September 30, 2007 and 2006 are as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
|
|
|
Nine Months Ended |
|
|
|
|
|
|
September 30, |
|
|
% |
|
September 30, |
|
|
% |
|
|
2007 |
|
|
2006 |
|
|
Change |
|
2007 |
|
|
2006 |
|
|
Change |
Consumer diagnostic products |
|
$ |
4,618 |
|
|
$ |
22,410 |
|
|
|
(79 |
)% |
|
$ |
51,640 |
|
|
$ |
63,586 |
|
|
|
(19 |
)% |
Vitamins and nutritional supplements |
|
|
2,605 |
|
|
|
828 |
|
|
|
215 |
% |
|
|
3,900 |
|
|
|
3,842 |
|
|
|
2 |
% |
Professional diagnostic products |
|
|
96,141 |
|
|
|
35,229 |
|
|
|
173 |
% |
|
|
189,881 |
|
|
|
86,316 |
|
|
|
120 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total gross
profit from net product sales |
|
$ |
103,364 |
|
|
$ |
58,467 |
|
|
|
77 |
% |
|
$ |
245,421 |
|
|
$ |
153,744 |
|
|
|
60 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer Diagnostic Products
Gross profit from our consumer diagnostic product sales decreased by $17.8 million, or 79%, to
$4.6 million for the three months ended September 30, 2007, compared to $22.4 million for the three
months ended September 30, 2006. The decrease during the three months ended September 30, 2007 is
primarily a result of the formation of the joint venture for our consumer diagnostics business on
May 17, 2007, partially offset by the gross profit earned on
28
revenue from acquired businesses, primarily our First Check acquisition, as discussed above,
and the 5% markup on products sold under our manufacturing agreement with Swiss Precision.
Gross profit from our consumer diagnostic product sales decreased by $11.9 million, or 19%, to
$51.6 million for the nine months ended September 30, 2007, compared to $63.6 million for the nine
months ended September 30, 2006. The decrease during the nine months ended September 30, 2007 is
primarily a result of the formation of the joint venture for our consumer diagnostics business on
May 17, 2007, partially offset by the gross profit earned on revenue from acquired businesses,
primarily our First Check acquisition, as discussed above, and the 5% markup on products sold under
our manufacturing agreement with Swiss Precision. Included in cost of sales for the nine months
ended September 30, 2006 was a $2.2 million restructuring charge related to the closure of our
Galway, Ireland manufacturing facility, the write-off of fixed assets impacted by our 2006
restructuring plans.
As a percentage of our consumer diagnostic net product sales, gross margin for the three and
nine months ended September 30, 2007 was 15% and 41%, respectively, compared to 51% and 49% for the
three and nine months ended September 30, 2006, respectively.
Vitamins and Nutritional Supplements
Gross profit in our vitamins and nutritional supplements business increased by $1.8 million,
to $2.6 million for the three months ended September 30, 2007, compared to $0.8 million for the
three months ended September 30, 2006. Gross profit in our vitamins and nutritional supplements
business increased by $0.1 million, or 2%, to $3.9 million for the nine months ended September 30,
2007, compared to $3.8 million for the nine months ended September 30, 2006. Gross profit was
relatively flat year over year for the nine-month periods.
As a percentage of our vitamins and nutritional supplements net product revenue, gross margin
for the three and nine months ended September 30, 2007 was 13% and 7%, respectively, compared to 4%
and 6% for the three and nine months ended September 30, 2006, respectively.
Professional Diagnostic Products
Gross profit from our professional diagnostic product sales increased by $60.9 million, or
173%, to $96.1 million during the three months ended September 30, 2007, compared to $35.2 million
for the three months ended September 30, 2006. The increase in gross profit was largely
attributable to the increase in product sales resulting primarily from our acquisitions of
Cholestech, Biosite and Instant, as discussed above, which contributed higher than average gross
profits.
Gross profit from our professional diagnostic product sales increased by $103.6 million, or
120%, to $189.9 million during the nine months ended September 30, 2007, compared to $86.3 million
for the nine months ended September 30, 2006. The increase in gross profit was largely attributable
to the increase in product sales resulting primarily from our acquisition of Cholestech, Biosite,
QAS, Instant, and the Innovacon business which contributed higher than average gross profits.
As a percentage of our professional diagnostic net product sales, gross margin for the three
and nine months ended September 30, 2007 was 54% and 54%, respectively, compared to 45% and 41% for
the three and nine months ended September 30, 2006, respectively.
Research and Development Expense. Research and development expense increased by $9.5 million,
or 86%, to $20.5 million for the three months ended September 30, 2007, compared to $11.1 million
for the three months ended September 30, 2006. The increase in research and development expense
during the three months ended September 30, 2007 was primarily related to our cardiology programs
and incremental spending associated with our acquired businesses, partially offset by the
transition of our consumer-related research and development efforts into our joint venture during
the second quarter of 2007. Research and development expense increased by $9.9 million, or 28%, to
$44.6 million for the nine months ended September 30, 2007, compared to $34.8 million for the nine
months ended September 30, 2006. The overall increased spending in the comparative nine-month
period was primarily related to our cardiology programs and incremental spending related to our
acquired businesses, partially offset by the transition of our consumer-related research and
development efforts into our joint venture during the second quarter
29
of 2007. Restructuring charges associated with our formation of the joint venture and our 2007
restructuring plan to integrate our newly acquired businesses totaling $0.3 million were included
in research and development expense for the three and nine months ended September 30, 2007.
Research and development expense of $20.5 million during the three months ended September 30,
2007 was partially offset by $4.8 million of funding from ITI earned during the three month period,
which represented an increase in funding of $0.5 million over the comparable three month period in
2006, and $0.2 million of unfavorable impact resulting from foreign currency translation. Research
and development expense of $44.6 million for the nine months ended September 30, 2007 was partially
offset by $13.7 million of funding from ITI earned during the nine month period, which represented
an increase in funding of $1.5 million over the comparable nine month period in 2006, and $0.9
million of unfavorable impact resulting from foreign currency translation.
Research and development expense included intangible amortization expense of $0.6 million and
$1.0 million for the three months ended September 30, 2007 and 2006, respectively, and $2.2 million
and $2.3 million for the nine months ended September 30, 2007 and 2006, respectively.
As a percentage of net product sales, research and development expense was 9% and 8% for the
three and nine months ended September 30, 2007, respectively, compared to 8% and 9% for the three
and nine months ended September 30, 2006, respectively.
Purchase of In-Process Research and Development (IPR&D). In connection with two of our
acquisitions since 2006, we have acquired various IPR&D projects. Substantial additional research
and development will be required prior to any of our acquired IPR&D programs and technology
platforms reaching technological feasibility. In addition, once research is completed, each product
candidate acquired will need to complete a series of clinical trials and receive FDA or other
regulatory approvals prior to commercialization. Our current estimates of the time and investment
required to develop these products and technologies may change depending on the different
applications that we may choose to pursue. We cannot give assurances that these programs will ever
reach technological feasibility or develop into products that can be marketed profitably. In
addition, we cannot guarantee that we will be able to develop and commercialize products before our
competitors develop and commercialize products for the same indications. If products based on our
acquired IPR&D programs and technology platforms do not become commercially viable, our results of
operations could be materially adversely affected. The following table sets forth IPR&D projects
for companies and certain assets we have acquired since 2006 (amounts in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discount Rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Used in |
|
|
|
|
|
|
|
Company/ |
|
|
|
|
|
|
|
|
|
|
|
|
Estimating |
|
|
Year of |
|
|
Estimated |
|
Year Assets |
|
|
Purchase |
|
|
|
|
|
|
|
|
Cash |
|
|
Expected |
|
|
Cost to |
|
Acquired |
|
|
Price |
|
|
IPR&D (1) |
|
|
Programs Acquired |
|
Flows(1) |
|
|
Launch |
|
|
Complete |
|
Biosite/2007 |
|
$ |
1,800,000 |
|
|
$ |
13,000 |
|
|
Triage Sepsis Panel |
|
|
15% |
|
|
|
2008-2010 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
156,000 |
|
|
Triage NGAL |
|
|
15% |
|
|
|
2008-2010 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
169,000 |
|
|
|
|
|
|
|
|
|
|
|
|
$ |
6,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clondiag/2006 |
|
$ |
24,000 |
|
|
$ |
1,800 |
|
|
CHF (Congestive Heart Failure) |
|
|
37% |
|
|
|
2008-2009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,500 |
|
|
ACS (Acute Coronary Syndrome) |
|
|
37% |
|
|
|
2009-2010 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
660 |
|
|
HIV (Human Immuno-deficiency Virus) |
|
|
37% |
|
|
|
2008-2009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
4,960 |
|
|
|
|
|
|
|
|
|
|
|
|
$ |
9,500 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Management assumes responsibility for determining the valuation of the acquired IPR&D
projects. The fair value assigned to IPR&D for each acquisition is estimated by discounting,
to present value, the cash flows expected once the acquired projects have reached
technological feasibility. The cash flows are probability adjusted to reflect the risks of
advancement through the product approval process. In estimating the future cash flows, we also
considered the tangible and intangible assets required for successful exploitation of the
technology resulting from the purchased IPR&D projects and adjusted future cash flows for a
charge reflecting the contribution to value of these assets. |
Sales and Marketing Expense. Sales and marketing expense increased by $22.6 million, or 87%,
to $48.5 million for the three months ended September 30, 2007, compared to $26.0 million for the
three months ended September 30, 2006. Sales and marketing expense increased by $35.3 million, or
51%, to $104.8 million for the nine months ended September 30, 2007, compared to $69.5 million for
the nine months ended September 30, 2006. The
30
increase in sales and marketing expense for the three months ended September 30, 2007 was
primarily the result of approximately $22.3 million of additional spending related to newly
acquired businesses, primarily Biosite, QAS, First Check, Instant, Cholestech and the various less
significant acquisitions, a $0.1 million charge related to our restructuring plan associated with
the formation of our joint venture and a $0.3 million of unfavorable impact resulting from foreign
currency translation. The increase in sales and marketing expense for the nine months ended
September 30, 2007 was primarily the result of approximately $29.9 million of additional spending
related to our acquisitions, primarily Biosite, First Check, QAS, Instant, the Innovacon business,
Cholestech and the various less significant acquisitions, higher advertising expenditures
associated with the introduction of our next generation branded digital pregnancy
test, a $0.4 million charge related to our restructuring plan associated
with the formation of our joint venture and $1.3
million of unfavorable impact resulting from foreign currency
translation.
Intangible asset amortization related to customer relationships is included in sales and
marketing expense. For the three and nine months ended September 30, 2007, sales and marketing
expense included intangible amortization expense of $11.6 million and $19.9 million, respectively.
For the three and nine months ended September 30, 2006, sales and marketing expense included
intangible amortization expense of $2.1 million and $5.3 million, respectively.
As a percentage of net product sales, sales and marketing expense was 21% and 20% for the
three and nine months ended September 30, 2007, respectively, compared to 18% and 17% for the three
and nine months ended September 30, 2006.
General and Administrative Expense. General and administrative expense increased $10.6
million, or 59%, to $28.7 million for the three months ended September 30, 2007, compared to $18.1
million for the three months ended September 30, 2006. General and administrative expense increased
$67.6 million, or 131%, to $119.2 million for the nine months ended September 30, 2007, compared to
$51.6 million for the nine months ended September 30, 2006. The increase in general and
administrative expense for the three months ended September 30, 2007 included approximately $8.4
million of additional spending related to our acquisitions of Biosite, Instant, QAS, Cholestech,
First Check and the various less significant acquisitions, a $0.1 million charge related to our
restructuring plan associated with the formation of our joint venture, an approximate $1.1
million increase in legal spending and $0.3 million of unfavorable impact
resulting from foreign currency translation. The increase in general and administrative expense for
the nine months ended September 30, 2007 included a $45.2 million stock option charge associated
with stock option acceleration and conversion in connection with our recent acquisition of Biosite,
approximately $12.9 million of additional spending related to our acquisitions, including Biosite,
Instant, the Innovacon business, First Check, QAS, Cholestech and the various less significant
acquisitions, a $0.2 million charge related to the formation of our joint venture mentioned above,
a $0.6 million restructuring charge related to the closure of our San Diego, California
manufacturing facility and $1.4 million of unfavorable impact resulting from foreign currency
translation, partially offset by a decrease in legal spending of $2.8 million.
General
and administrative expense included intangible amortization expense of $0.1 million
and $0.1 million for the three months ended September 30, 2007 and 2006, and $0.2 million and $0.3
million for the nine months ended September 30, 2007 and 2006, respectively. The amortization
expense recorded to general and administrative expense relates primarily to non-compete agreements.
As a percentage of net revenue, general and administrative expense for the three and nine
months ended September 30, 2007 was 12% and 22%, respectively, compared to 12% and 13% for the
three and nine months ended September 30, 2006, respectively.
Loss on Dispositions, Net. During the nine months ended September 30, 2006, we recorded a net
loss of $3.2 million. Included in this charge is a loss of $4.6 million associated with
managements decision to dispose of our SMB research operation. The $4.6 million charge included a
loss of $2.0 million on impaired assets, most of which represents goodwill associated with SMB, and
a $2.6 million estimated loss on the sale of SMB. We disposed of this operation in the fourth
quarter of 2006. The $4.6 million loss is offset by a $1.4 million gain on the sale of an idle
manufacturing facility in Galway, Ireland, as a result of our 2005 restructuring plan.
Interest Expense. Interest expense included interest charges, the write-off and amortization
of deferred financing costs, prepayment premiums, and the amortization of non-cash discounts
associated with our debt
31
issuances. Interest expense increased by $20.8 million, or 254%, to $29.0 million for the
three months ended September 30, 2007, compared to $8.2 million for the three months ended
September 30, 2006. Interest expense increased by $35.4 million, or 170%, to $56.2 million for the
nine months ended September 30, 2007, compared to $20.8 million for the nine months ended September
30, 2006. Interest expense for the nine months ended September 30, 2007 included the write-off of
$15.6 million of deferred financing costs and prepayment premium related to the repayment of
outstanding debt, in conjunction with our financing arrangements related to our Biosite
acquisition. Interest expense increased for both periods as a result
of higher debt balances than in prior periods.
Other Income (Expense), Net. Other income (expense), net includes interest income, realized
and unrealized foreign exchange gains and losses, and other income and expense. The components and
the respective amounts of other income (expense), net are summarized as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
|
|
|
Nine Months Ended |
|
|
|
|
|
|
September 30, |
|
|
$ |
|
|
September 30, |
|
|
$ |
|
|
|
2007 |
|
|
2006 |
|
|
Change |
|
|
2007 |
|
|
2006 |
|
|
Change |
|
Interest income |
|
$ |
1,412 |
|
|
$ |
439 |
|
|
$ |
973 |
|
|
$ |
7,678 |
|
|
$ |
1,058 |
|
|
$ |
6,620 |
|
Foreign exchange gains (losses), net |
|
|
1,290 |
|
|
|
(107 |
) |
|
|
1,397 |
|
|
|
2,615 |
|
|
|
3,236 |
|
|
|
(621 |
) |
Other |
|
|
(559 |
) |
|
|
(1,245 |
) |
|
|
686 |
|
|
|
(1,471 |
) |
|
|
(334 |
) |
|
|
(1,137 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income (expense), net |
|
$ |
2,143 |
|
|
$ |
(913 |
) |
|
$ |
3,056 |
|
|
$ |
8,822 |
|
|
$ |
3,960 |
|
|
$ |
4,862 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income of $1.4 million and $7.7 million for the three and nine months ended September
30, 2007, respectively, increased $1.0 million and $6.6 million, respectively, compared to the
three and nine months ended September 30, 2006, respectively. This increase was primarily the
result of interest earned on higher cash balances.
Included in foreign exchange gains (losses), net for the nine months ended September 30, 2007
was a $1.9 million foreign exchange realized upon the settlement of intercompany notes. Included in
foreign exchange gains (losses), net for the nine months ended September 30, 2006 was a $4.3
million unrealized foreign exchange gain associated with the closure of our Galway, Ireland
manufacturing facility.
Other loss of $0.5 million for the three months ended September 30, 2007, primarily reflects
minority interest expense related to our less than wholly-owned subsidiaries and other investments.
Other loss of $1.5 million for the nine months ended September 30, 2007, primarily reflects
minority interest expense related to our less than wholly-owned subsidiaries, partially offset by a
$0.8 million gain which resulted from a favorable adjustment to the rental terms of one of our
leased facilities. Other loss of $1.2 million for the three months ended September 30, 2006
included $1.5 million of charges related to two legal settlements during this period In addition
to the $1.5 million in legal settlements is a $0.8 million gain on a legal settlement related to
the resolution of a contingency related to our 2003 acquisition of ABI,
and $0.2 million of additional expense related to a legal settlement of a class action suit against
several raw material suppliers in our vitamins and nutritional supplements business.
(Benefit) Provision for Income Taxes. An income tax benefit of $1.6 million was reported for
the three months ended September 30, 2007, compared to a provision for income taxes of $1.6 million
for the three months ended September 30, 2006. Provision for incomes taxes was $1.6 million for the
nine months ended September 30, 2007, compared to $3.9 million for the nine months ended September
30, 2006. The effective tax rate was 0.9% and (0.7)% for the three and nine months ended September
30, 2007, respectively, compared to (20)% for both the three and nine months ended September 30,
2006. The income tax benefit for the three months ended September 30, 2007 includes $2.4 million of
benefit relating to the recognition of US federal and state losses, as well as foreign losses and
net operating loss (NOL) utilization. Other components of the tax provision include a state income tax provision and
foreign income tax provisions for various foreign subsidiaries.
Equity Earnings in Unconsolidated Entities, Net of Tax. Equity earnings in unconsolidated
entities is reported net of tax and includes our share of earnings in entities that we account for
under the equity method of accounting. Equity earnings in unconsolidated entities for the three and
nine months ended September 30, 2007 reflects the following: (i) our 50% interest in our newly
formed joint venture with P&G in the amount of $0.7 million and $1.7 million, respectively, (ii)
our 40% interest in Vedalab S.A. in the amount of $178,000 and $0.2 million, respectively, and
(iii) our 49% interest in TechLab, Inc. in the amount of $0.2 million and $0.8 million,
respectively.
32
Net
Loss. We incurred a net loss of $180.6 million, or $3.74 per basic and diluted common
share, for the three months ended September 30, 2007, compared to a net loss of $9.7 million, or
$0.27 per basic and diluted common share, for the three months ended September 30, 2006. We
incurred net loss of $229.0 million, or $4.89 per basic and diluted common share, for the nine
months ended September 30, 2007, compared to a net loss of $22.9 million, or $0.70 per basic and
diluted common share, for the nine months ended September 30, 2006. The increases in net loss for
the three and nine months ended September 30, 2007, compared to the three and nine months ended
September 30, 2006, primarily resulted from the various factors as discussed above. See Note 6 of
the accompanying consolidated financial statements for the calculation of net loss per common
share.
Liquidity and Capital Resources
Based upon our current working capital position, current operating plans and expected business
conditions, we believe that our existing capital resources and credit facilities will be adequate to fund our
operations, including our outstanding debt and other commitments, as discussed below, for the next
12 months. In the long run, we expect to fund our working capital needs and other commitments
primarily through our operating cash flow, which we expect to improve as we improve our operating
margins, execute our restructuring plans, grow our business through new product introductions, business acquisitions and by continuing to leverage our
strong intellectual property position. We also expect to rely on our credit facilities to fund a
portion of our capital needs and other commitments. We may also access public equity and debt markets where consistent with our strategic or financial objectives.
Our funding plans for our working capital needs and other commitments may be adversely
impacted by unexpected costs associated with prosecuting and defending our existing lawsuits and/or
unforeseen lawsuits against us, integrating the operations of newly acquired companies and
executing our cost savings strategies. We also cannot be certain that our underlying assumed levels
of revenues and expenses will be realized. In addition, we intend to continue to make significant
investments in our research and development efforts related to the substantial intellectual
property portfolio we own. We may also choose to further expand our research and development
efforts and may pursue the acquisition of new products and technologies through licensing
arrangements, business acquisitions, or otherwise. We may also choose to make significant
investment to pursue legal remedies against potential infringers of our intellectual property. If
we decide to engage in such activities, or if our operating results fail to meet our expectations,
we could be required to seek additional funding through public or private financings or other
arrangements. In such event, adequate funds may not be available when needed, or, may be available
only on terms which could have a negative impact on our business and results of operations. In
addition, if we raise additional funds by issuing equity or convertible securities, dilution to
then existing stockholders may result.
Summary of Changes in Cash Position
As of September 30, 2007, we had cash and cash equivalents of $153.3 million, an $82.2 million
increase from December 31, 2006. Our primary sources of cash during the nine months ended September
30, 2007 included $301.0 million in net proceeds from the issuance of our common stock in
connection with our January 2007 offering, as well as common stock issues under employee stock
option and stock purchase plans, $324.2 million of net cash proceeds from P&G, associated with the
formation of our 50/50 joint venture, approximately $1.1 billion of cash from our refinancing
activities, net of repayments related to our previous credit
facilities and notes, and $34.0
million of cash generated by operating activities. Investing activities during the nine months
ended September 30, 2007 used a total of approximately $1.3 billion of cash, net of cash acquired,
primarily related to our acquisition activities. Fluctuations in foreign currencies favorably
impacted our cash balance by $6.9 million during the nine months ended September 30, 2007.
Operating Cash Flows
Net cash provided by operating activities during the nine months ended September 30, 2007 was
$34.0 million, which resulted from $293.0 million of non-cash items, offset by our net loss of
$229.0 million and $30.0 million of cash used to meet net working capital requirements during the
period. The $293.0 million of non-cash items included a $169.0 million charge associated with the
write-off of IPR&D in connection with our acquisition of Biosite, $61.6 million related to
depreciation and amortization and $46.9 million related to non-cash stock-based compensation
expense.
33
Investing Cash Flows
Our investing activities during the nine months ended September 30, 2007 utilized
approximately $1.3 billion of net cash, including $1.6 billion used for acquisitions and
transaction-related costs, net of cash acquired, $13.4 million of cash related to minority
investment activities, $21.5 million of capital expenditures, net of proceeds from sale of
equipment, a $29.5 million increase in other assets, offset by net cash proceeds of $324.2 million
related to the formation of our 50/50 joint venture with P&G.
Significant acquisitions during the nine months ending September 30, 2007 included Biosite,
QAS, Instant and First Check, which accounted for the $1.6 billion in cash, net of cash
acquired, used for acquisitions.
Financing Cash Flows
On January 31, 2007, we sold an aggregate 6,000,000 shares of our common stock at $39.65 per
share through an underwritten public offering, and on February 5, 2007, our underwriters exercised
in full an option to purchase an additional 900,000 shares to cover over-allotments. Proceeds from
the offering were approximately $261.3 million, net of issuance costs of $12.3 million, which
include deductions for underwriting discounts and commissions and take into effect the
reimbursement by the underwriters of a portion of our offering expenses. Of this amount, we used
$44.9 million to repay all principal and accrued interest owing on the term loan under our senior
credit facility, with the remainder of the net proceeds retained for working capital and other
general corporate purposes.
On June 26, 2007, in connection with our acquisition of Biosite, we entered into a secured
First Lien Credit Agreement and a secured Second Lien Credit Agreement (collectively, the Credit
Agreement) with certain lenders, General Electric Capital Corporation as administrative agent and
collateral agent, and certain other agents and arrangers, and certain related guaranty and security
agreements. The First Lien Credit Agreement provides for term loans in the aggregate amount of
$900.0 million and, subject to our continued compliance with the First Lien Credit Agreement, a
$150.0 million revolving line of credit. The Second Lien Credit Agreement provides for term loans
in the aggregate amount of $250.0 million. As of September 30, 2007, aggregate borrowings amounted
to $41.0 million under the revolving line of credit and $1.1 billion under the term loans. Interest expense
related to our new credit facility which included the term loans and revolving line of credit for
the three and nine months ended September 30, 2007, including amortized deferred costs, was $27.5
million and $29.2 million, respectively. As of September 30, 2007, we were in compliance with all
debt covenants related to the above debt.
Simultaneously with our entry into the Credit Agreements, we terminated our existing third
amended and restated credit agreement dated June 30, 2005 (the Prior Credit Agreement). We had no
outstanding loans under the Prior Credit Agreement at the time it was terminated.
In addition, on June 26, 2007, we also fully repaid our 8.75% senior subordinated notes due
2012 (the Notes). The total amount repaid, including principal of $150.0 million and a prepayment
premium of $9.3 million, was $159.3 million. Accrued interest of $4.8 million was also paid as part
of the final settlement of these Notes and unamortized deferred financing costs of $3.7 million
were written off as a result of the repayment.
Additionally, we received proceeds from the May 14, 2007 sale of $150.0 million principal
amount of 3% convertible senior subordinated notes due 2016 (the Convertible Notes) in a private
placement to qualified institutional buyers to help finance the Biosite acquisition. At the initial
conversion price of $52.30, the Convertible Notes are convertible into an aggregate 2,868,120
shares of our common stock. The conversion price is subject to adjustment one year from the date of
sale if the 30 day volume-weighted average trading price of our common stock as of such date is
lower than $40.23, subject to a floor of $40.23, or from time to time in the event of stock splits,
stock dividends, recapitalizations and other similar events. The conversion price is also subject
to a make-whole payment in the form of an adjustment to the conversion price in the event of a
fundamental change (as defined in the Indenture). Interest accrues at 3% per annum, compounded
daily, on the outstanding principal amount and is payable in arrears on May 15th and Nov 15th,
which will start on November 15, 2007. Interest expense for the three and nine months ended
September 30, 2007, including amortized deferred costs, was $1.2 million and $1.8 million,
respectively.
In August 2007, we entered into interest rate swap contracts, with an effective date of
September 28, 2007, that have a total notional value of $350.0 million and have a maturity date of
September 28, 2010. These interest rate swap contracts will pay us variable interest at the
three-month LIBOR rate, and we will pay the counterparties a fixed rate of 4.85%. These interest
rate swap contracts were entered into to convert $350.0 million of the $1.3 billion variable rate
term loan under the senior credit facility into fixed rate debt. Based on the terms of the interest
rate swap contracts and the underlying debt, these interest rate swap contracts were determined to
be effective, and thus qualify as a cash flow hedge under SFAS No. 133, Accounting for Derivative
Instruments and Hedging Activities. As such, any changes in the fair value of these interest rate
swaps are recorded in other comprehensive income on the accompanying consolidated balance sheet
until earnings are affected by the variability of cash flows.
34
As of September 30, 2007 we had an aggregate of $0.8 million in outstanding capital lease
obligations which are payable through 2011.
Income Taxes
As of December 31, 2006, we had approximately $188.7 million of domestic NOL carryforward
and $33.3 million of foreign NOL carryforward, respectively, which either
expire on various dates through 2026 or can be carried forward indefinitely. These losses are
available to reduce federal and foreign taxable income, if any, in future years. These losses are
also subject to review and possible adjustments by the applicable taxing authorities. In addition,
the domestic NOL carryforward amount at December 31, 2006 included approximately $70.5
million of pre-acquisition losses at Inverness Medical Nutritionals
Group, Ischemia Technologies, Inc., Ostex International, Inc. and
Advantage Diagnostics Corporation and the foreign NOL carryforward amount included approximately $12.7 million of
pre-acquisition losses at Clondiag. The future benefit of these losses will be applied first to
reduce to zero any goodwill and other non-current intangible assets related to the acquisitions,
prior to reducing our income tax expense. Also included in our domestic NOL carryforward at
December 31, 2006 was approximately $2.6 million resulting from the exercise of employee stock
options, the tax benefit of which, when recognized, will be accounted for as a credit to additional
paid-in capital rather than a reduction of income tax.
Furthermore, all domestic losses are subject to the Internal Revenue Service Code Section 382
limitation and may be limited in the event of certain cumulative changes in ownership interests of
significant shareholders over a three-year period in excess of 50%. Section 382 imposes an annual
limitation on the use of these losses to an amount equal to the value of the company at the time of
the ownership change multiplied by the long-term tax exempt rate.
Off-Balance Sheet Arrangements
In
August 2007, we entered into interest rate swap contracts, with
an effective date of September 28, 2007, that have a total notional value
of $350.0 million and have a maturity date of September 28, 2010. These interest rate swap
contracts will pay us variable interest at the three-month LIBOR rate, and we will pay the
counterparties a fixed rate of 4.85%. These interest rate swap contracts were entered into to
convert $350.0 million of the $1.3 billion variable rate term loan under the senior credit facility
into fixed rate debt. Based on the terms of the interest rate swap contracts and the underlying
debt, these interest rate swap contracts were determined to be effective, and thus qualify as a
cash flow hedge under SFAS No. 133. As such, any changes in the fair value of these interest rate swaps are recorded
in other comprehensive income on the accompanying consolidated balance sheet until earnings are
affected by the variability of cash flows.
Contractual Obligations
The following table summarizes our principal contractual obligations as of September 30, 2007
that have changed significantly since December 31, 2006 and the effects such obligations are
expected to have on our liquidity and cash flow in future periods. Contractual obligations that
were presented in our Annual Report on Form 10-K/A for the year ended December 31, 2006 but omitted
in the table below represent those that have not changed significantly since that date.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments Due by Period |
|
Contractual Obligations |
|
Total |
|
|
2007 |
|
|
2008-2009 |
|
|
2010-2011 |
|
|
Thereafter |
|
|
|
(in thousands) |
|
Long-term debt obligations (1) |
|
$ |
1,349,364 |
|
|
$ |
4,885 |
|
|
$ |
5,614 |
|
|
$ |
115 |
|
|
$ |
1,338,750 |
|
Capital lease obligation |
|
|
808 |
|
|
|
176 |
|
|
|
495 |
|
|
|
137 |
|
|
|
|
|
Purchase obligations capital expenditures |
|
|
12,555 |
|
|
|
12,555 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase obligations Innovacon business (2) |
|
|
6,000 |
|
|
|
6,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest on debt (3) |
|
|
40,500 |
|
|
|
2,823 |
|
|
|
9,000 |
|
|
|
9,000 |
|
|
|
19,677 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
1,409,227 |
|
|
$ |
26,439 |
|
|
$ |
15,109 |
|
|
$ |
9,252 |
|
|
$ |
1,358,427 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Long-term debt obligations increased by $1.1 billion since December 31, 2006, primarily due
to our new credit facility in connection with our acquisition of Biosite, during the nine
months ended September 30, 2007. |
|
(2) |
|
In connection with our acquisition of the Innovacon business, we are obligated to make a $6.0
million payment for the remaining first territory business. |
35
|
|
|
(3) |
|
Amounts are based on $150.0 million, 3% convertible senior subordinated notes. Amounts
exclude interest on all other debt due to variable interest rates. |
As of September 30, 2007, we had contingent consideration obligations related to our
acquisitions of Spectral/Source, Instant, First Check, Binax, Inc. (Binax) and CLONDIAG chip
technologies Gmbh (Clondiag). The contingent considerations will be accounted for as increases in
the aggregate purchase prices if and when the contingencies occur.
With respect to Spectral/Source, we will pay an earn-out equal to two times the consolidated
revenue of Spectral/Source less $4.0 million, if the consolidated profits before tax of
Spectral/Source is at least $0.9 million on the one year anniversary (milestone period) following
the acquisition date. If consolidated profits before tax of Spectral/Source for the milestone
period are less than $0.9 million, then the amount of the payment will be equal to seven times
Spectral/Sources consolidated profits before tax less $4.0 million. The contingent consideration
is payable 60% in cash and 40% in stock.
With respect to Instant, the terms of the acquisition agreement provide for $16.6 million of
contingent consideration payable in cash or cash and stock to acquire the remaining 25% ownership
interest in Instant. The seller has the option, but is not obligated, to sell his remaining 25%
during the four-year period commencing April 1, 2008 and ending March 31, 2012. The option is
contingent upon the business meeting certain revenue and gross profit targets or may be triggered
should the seller be terminated as an employee, without cause. The option shall terminate if not
exercised during the period mentioned above. Furthermore, we have the option, but not an
obligation, to acquire the remaining 25% from the seller on or before March 31, 2012 for $24.6
million in cash or cash and stock. If the seller is not an employee of the company at the time of
exercise, the full consideration shall be payable in cash. The option shall terminate if not
exercised during the period mentioned above.
With respect to First Check, we will pay an earn-out to First Check equal to the incremental
revenue growth of the acquired products for 2007 and for the first nine months of 2008, as compared
to the immediately preceding comparable periods.
With respect to Binax, the terms of the acquisition agreement provide for $11.0 million of
contingent cash consideration payable to the Binax shareholders upon the successful completion of
certain new product developments during the five years following the acquisition. Successful
development of one of the qualifying products was completed during the second quarter of 2007 for
which we made a payment in the amount of $3.7 million during the third quarter.
With respect to Clondiag, the terms of the acquisition agreement provide for $8.9 million of
contingent consideration, consisting of 224,316 shares of our common stock and approximately $3.0
million of cash or stock in the event that four specified products are developed on Clondiags
platform technology during the three years following the acquisition date.
Critical Accounting Policies
The consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q
are prepared in accordance with accounting principles generally accepted in the United States of
America, or GAAP. The accounting policies discussed below are considered by our management and our
audit committee to be critical to an understanding of our financial statements because their
application depends on managements judgment, with financial reporting results relying on estimates
and assumptions about the effect of matters that are inherently uncertain. Specific risks for these
critical accounting policies are described in the following paragraphs. For all of these policies,
management cautions that future events rarely develop exactly as forecast and the best estimates
routinely require adjustment. In addition, the notes to our audited consolidated financial
statements for the year ended December 31, 2006 included in our Annual Report on Form 10-K/A
include a comprehensive summary of the significant accounting policies and methods used in the
preparation of our consolidated financial statements.
36
Revenue Recognition
We primarily recognize revenue when the following four basic criteria have been met: (1)
persuasive evidence of an arrangement exists; (2) delivery has occurred or services rendered; (3)
the fee is fixed and determinable; and (4) collection is reasonably assured.
The majority of our revenue is derived from product sales. We recognize revenue upon title
transfer of the products to third-party customers, less a reserve for estimated product returns and
allowances. Determination of the reserve for estimated product returns and allowances is based on
our managements analyses and judgments regarding certain conditions, as discussed below in the
critical accounting policy Use of Estimates for Sales Returns and Other Allowances and Allowance
for Doubtful Accounts. Should future changes in conditions prove managements conclusions and
judgments on previous analyses to be incorrect, revenue recognized for any reporting period could
be adversely affected.
In connection with the acquisition of the Determine business in June 2005 from Abbott
Laboratories, we entered into a manufacturing support services agreement with Abbott, whereby
Abbott would continue to distribute certain of the acquired products for a period of up to 30
months following the acquisition, subject to certain extensions. During the transition period, we
recognized revenue on sales of the products when title transferred from Abbott to third party
customers.
We also receive license and royalty revenue from agreements with third-party licensees.
Revenue from fixed fee license and royalty agreements are recognized on a straight-line basis over
the obligation period of the related license agreements. License and royalty fees that the
licensees calculate based on their sales, which we have the right to audit under most of our
agreements, are generally recognized upon receipt of the license or royalty payments unless we are
able to reasonably estimate the fees as they are earned. License and royalty fees that are
determinable prior to the receipt thereof are recognized in the period they are earned.
Use of Estimates for Sales Returns and Other Allowances and Allowance for Doubtful Accounts
Certain sales arrangements require us to accept product returns. From time to time, we also
enter into sales incentive arrangements with our retail customers, which generally reduce the sale
prices of our products. As a result, we must establish allowances for potential future product
returns and claims resulting from our sales incentive arrangements against product revenue
recognized in any reporting period. Calculation of these allowances requires significant judgments
and estimates. When evaluating the adequacy of the sales returns and other allowances, our
management analyzes historical returns, current economic trends, and changes in customer and
consumer demand and acceptance of our products. When such analysis is not available and a right of
return exists the Company records revenue when the right of return is no longer applicable.
Material differences in the amount and timing of our product revenue for any reporting period may
result if changes in conditions arise that would require management to make different judgments or
utilize different estimates.
Our total provision for sales returns and other allowances related to sales incentive
arrangements amounted to $12.3 million and $39.4 million, or 5% and 7%, respectively, of product
sales for the three and nine months ended September 30, 2007, respectively, compared to $14.2
million and $38.8 million, or 9% and 9%, respectively, of product sales for the three and nine
months ended September 30, 2006, respectively, which have been recorded against product sales to
derive our net product sales. Our provision for sales returns and other allowances are primarily
related to our consumer diagnostic business, which transferred into our joint venture. The
remaining balances relate to sales made on or prior to May 17, 2007, the day prior to the effective
date of the joint venture.
Similarly, our management must make estimates regarding uncollectible accounts receivable
balances. When evaluating the adequacy of the allowance for doubtful accounts, management analyzes
specific accounts receivable balances, historical bad debts, customer concentrations, customer
credit-worthiness, current economic trends and changes in our customer payment terms and patterns.
Our accounts receivable balance was $122.8 million and $100.4 million, net of allowances for
doubtful accounts of $8.4 million and $8.4 million, as of September 30, 2007 and December 31, 2006,
respectively.
37
Valuation of Inventories
We state our inventories at the lower of the actual cost to purchase or manufacture the
inventory or the estimated current market value of the inventory. In addition, we periodically
review the inventory quantities on hand and record a provision for excess and obsolete inventory.
This provision reduces the carrying value of our inventory and is calculated based primarily upon
factors such as forecasts of our customers demands, shelf lives of our products in inventory, loss
of customers, manufacturing lead times and, less commonly, decisions to withdraw our products from
the market. Evaluating these factors, particularly forecasting our customers demands, requires
management to make assumptions and estimates. Actual product sales may prove our forecasts to be
inaccurate, in which case we may have underestimated or overestimated the provision required for
excess and obsolete inventory. If, in future periods, our inventory is determined to be overvalued,
we would be required to recognize the excess value as a charge to our cost of sales at the time of
such determination. Likewise, if, in future periods, our inventory is determined to be undervalued,
we would have over-reported our cost of sales, or understated our earnings, at the time we recorded
the excess and obsolete provision. Our inventory balance was $136.5 million and $78.3 million, net
of a provision for excess and obsolete inventory of $6.2 million and $8.2 million, as of September
30, 2007 and December 31, 2006, respectively.
Valuation of Goodwill and Other Long-Lived and Intangible Assets
Our long-lived assets include: (1) property, plant and equipment, (2) goodwill and (3) other
intangible assets. As of September 30, 2007, the balances of property, plant and equipment,
goodwill and other intangible assets, net of accumulated depreciation and amortization, were $243.1
million, $1.4 billion and $1.1 billion, respectively.
Goodwill and other intangible assets are initially created as a result of business
combinations or acquisitions of intellectual property. The values we record for goodwill and other
intangible assets represent fair values calculated by accepted valuation methods. Such valuations
require us to provide significant estimates and assumptions which are derived from information
obtained from the management of the acquired businesses and our business plans for the acquired
businesses or intellectual property. Critical estimates and assumptions used in the initial
valuation of goodwill and other intangible assets include, but are not limited to: (1) future
expected cash flows from product sales, customer contracts and acquired developed technologies and
patents, (2) expected costs to complete any in-process research and development projects and
commercialize viable products and estimated cash flows from sales of such products, (3) the
acquired companies brand awareness and market position, (4) assumptions about the period of time
over which we will continue to use the acquired brand and (5) discount rates. These estimates and
assumptions may be incomplete or inaccurate because unanticipated events and circumstances may
occur. If estimates and assumptions used to initially value goodwill and intangible assets prove to
be inaccurate, ongoing reviews of the carrying values of such goodwill and intangible assets, as
discussed below, may indicate impairment which will require us to record an impairment charge in
the period in which we identify the impairment.
Where we believe that property, plant and equipment and intangible assets have finite lives,
we depreciate and amortize those assets over their estimated useful lives. For purposes of
determining whether there are any impairment losses, as further discussed below, our management has
historically examined the carrying value of our identifiable long-lived tangible and intangible
assets and goodwill, including their useful lives where we believe such assets have finite lives,
when indicators of impairment are present. In addition, Statement of Financial Accounting Standards
(SFAS) No. 142, Goodwill and Other Intangible Assets, requires that impairment reviews be
performed on the carrying values of all goodwill on at least an annual basis. For all long-lived
tangible and intangible assets and goodwill, if an impairment loss is identified based on the fair
value of the asset, as compared to the carrying value of the asset, such loss would be charged to
expense in the period we identify the impairment. Furthermore, if our review of the carrying values
of the long-lived tangible and intangible assets with finite lives indicates impairment of such
assets, we may determine that shorter estimated useful lives are more appropriate. In that event,
we will be required to record additional depreciation and amortization in future periods, which
will reduce our earnings.
Valuation of Goodwill
We have goodwill balances related to our consumer diagnostics and professional diagnostics
reporting segments, which amounted to $88.3 million and $1.3 billion, respectively, as of September
30, 2007. As of September 30,
38
2006, we performed our annual impairment review on the carrying values of such goodwill using
the discounted cash flows approach. Based upon this review, we do not believe that the goodwill
related to our consumer diagnostics and professional diagnostics reporting units were impaired.
Because future cash flows and operating results used in the impairment review are based on
managements projections and assumptions, future events can cause such projections to differ from
those used at September 30, 2006, which could lead to significant impairment charges of goodwill in
the future. No events or circumstances have occurred since our review as of September 30, 2006,
that would require us to reassess whether the carrying values of our goodwill have been impaired.
Valuation of Other Long-Lived Tangible and Intangible Assets
Factors we generally consider important which could trigger an impairment review on the
carrying value of other long-lived tangible and intangible assets include the following: (1)
significant underperformance relative to expected historical or projected future operating results;
(2) significant changes in the manner of our use of acquired assets or the strategy for our overall
business; (3) underutilization of our tangible assets; (4) discontinuance of product lines by
ourselves or our customers; (5) significant negative industry or economic trends; (6) significant
decline in our stock price for a sustained period; (7) significant decline in our market
capitalization relative to net book value; and (8) goodwill impairment identified during an
impairment review under SFAS No. 142. Although we believe that the carrying value of our long-lived
tangible and intangible assets was realizable as of September 30, 2007, future events could cause
us to conclude otherwise.
Stock-Based Compensation
As of January 1, 2006, we account for stock-based compensation in accordance with SFAS No.
123-R, Share-Based Payment. Under the fair value recognition provisions of this statement,
share-based compensation cost is measured at the grant date based on the value of the award and is
recognized as expense over the vesting period. Determining the fair value of share-based awards at
the grant date requires judgment, including estimating our stock price volatility and employee
stock option exercise behaviors. If actual results differ significantly from these estimates,
stock-based compensation expense and our results of operations could be materially impacted.
Our expected volatility is based upon the historical volatility of our stock. We have chosen
to utilize the simplified method to calculate the expected life of options which averages an
awards weighted average vesting period and its contractual term. As stock-based compensation
expense is recognized in our consolidated statement of operations is based on awards ultimately
expected to vest, the amount of expense has been reduced for estimated forfeitures. SFAS No. 123-R
requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent
periods if actual forfeitures differ from those estimates. Forfeitures were estimated based on
historical experience. If factors change and we employ different assumptions in the application of
SFAS No.123-R, the compensation expense that we record in future periods may differ significantly
from what we have recorded in the current period.
Accounting for Income Taxes
As part of the process of preparing our consolidated financial statements, we are required to
estimate our income taxes in each of the jurisdictions in which we operate. This process involves
us estimating our actual current tax exposure and assessing temporary differences resulting from
differing treatment of items, such as reserves and accruals and lives assigned to long-lived and
intangible assets, for tax and accounting purposes. These differences result in deferred tax assets
and liabilities. We must then assess the likelihood that our deferred tax assets will be recovered
through future taxable income and, to the extent we believe that recovery is not likely, we must
establish a valuation allowance. To the extent we establish a valuation allowance or increase this
allowance in a period, we must include an expense within our tax provision.
Significant management judgment is required in determining our provision for income taxes, our
deferred tax assets and liabilities and any valuation allowance recorded against our net deferred
tax assets. We recorded a valuation allowance of $107.6 million as of December 31, 2006 due to
uncertainties related to the future benefits, if any, from our deferred tax assets related
primarily to our U.S. businesses and certain foreign net operating losses and tax credits. The
valuation allowance is based on our estimates of taxable income by jurisdiction in which we operate
and the period over which our deferred tax assets will be recoverable. In the event that actual
results differ from
39
these estimates or we adjust these estimates in future periods, we may need to establish an
additional valuation allowance or reduce our current valuation allowance which could materially
impact our tax provision. We recorded approximately $262.8 million of U.S. jurisdiction non-current
deferred tax liabilities through purchase accounting related to the Biosite acquisition during the
third quarter of 2007. Due to this change, we determined that approximately $96.0 million of
valuation allowance relating to U.S. NOLs and other U.S. deferred tax
assets should be released and recorded as a reduction of goodwill in
the accompanying consolidated balance sheets.
Therefore, we reduced our valuation allowance to $11.6 million as of September 30, 2007.
On January 1, 2007 we adopted Financial Accounting Standards Board (FASB) Interpretation No.
48 (FIN 48), Accounting for Uncertainty in Income Taxes an Interpretation of FASB Statement
109. In accordance with FIN 48, we established reserves for tax uncertainties that reflect the use
of the comprehensive model for the recognition and measurement of uncertain tax positions. We are
currently undergoing routine tax examinations by various state and foreign jurisdictions. Tax
authorities periodically challenge certain transactions and deductions we reported on our income
tax returns. We do not expect the outcome of these examinations, either individually or in the
aggregate, to have a material adverse effect on our financial position, results of operations, or
cash flows.
Prior to January 1, 2007 in accordance with SFAS No. 109, Accounting for Income Taxes, and
SFAS No. 5, Accounting for Contingencies, we established reserves for tax contingencies that
reflect our best estimate of the transactions and deductions that we may be unable to sustain or
that we could be willing to concede as part of a broader tax settlement.
It has been our practice to permanently reinvest all foreign earnings into foreign operations
and we currently expect to continue to reinvest foreign earnings permanently into our foreign
operations. Should we plan to repatriate any foreign earnings in the future, we will be required to
establish an income tax expense and related tax liability on such earnings.
Loss Contingencies
In the section of our Annual Report on Form 10-K/A for the year ended December 31, 2006,
titled Item 3. Legal Proceedings, we have reported on material legal proceedings. In addition,
because of the nature of our business, we may from time to time be subject to commercial disputes,
consumer product claims or various other lawsuits arising in the ordinary course of our business,
and we expect this will continue to be the case in the future. These lawsuits generally seek
damages, sometimes in substantial amounts, for commercial or personal injuries allegedly suffered
and can include claims for punitive or other special damages. In addition, we aggressively defend
our patent and other intellectual property rights. This often involves bringing infringement or
other commercial claims against third parties, which can be expensive and can results in
counterclaims against us.
We do not accrue for potential losses on legal proceedings where our company is the defendant
when we are not able to reasonably estimate our potential liability, if any, due to uncertainty as
to the nature, extent and validity of the claims against us, uncertainty as to the nature and
extent of the damages or other relief sought by the plaintiff and the complexity of the issues
involved. Our potential liability, if any, in a particular case may become reasonably estimable and
probable as the case progresses, in which case we will begin accruing for the expected loss.
Derivative Financial Instruments
We use derivative financial instruments (interest rate swap contracts) in the management of
our interest rate exposure related to our senior credit facilities. We do not hold or issue
derivative financial instruments for speculative purposes.
Based on the terms of the interest rate swap contracts and the underlying debt, these
contracts were determined to be effective, and thus qualify as a cash flow hedge under SFAS No.
133. We record our interest rate swap contracts on the balance sheet at fair value which, at
September 30, 2007 was $0, based on the inception date of September 28, 2007. As a designated cash
flow hedge, changes in the fair value of these interest rate swaps are recorded in accumulated
other comprehensive income on the accompanying consolidated balance sheet until earnings are
affected by the variability of cash flows.
Recent Accounting Pronouncements
Recently Issued Accounting Standards
In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements. SFAS No. 157
establishes a framework for measuring fair value in generally accepted accounting principles, and
expands disclosures about fair value measurements. The standard applies whenever other standards
require (or permit) assets or liabilities to be measured at fair value. The standard does not
expand the use of fair value in any new circumstances. SFAS No. 157 is effective for financial
statements issued for fiscal years beginning after November 15, 2007, and interim periods within
those fiscal years. Earlier application is encouraged. We continue to evaluate the impact that the
adoption of SFAS No. 157 will have, if any, on our consolidated financial statements.
In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and
Financial Liabilities Including an Amendment of FASB No 115. This Statement provides companies
with an option to
40
measure, at specified election dates, many financial instruments and certain other items at
fair value that are not currently measured at fair value. The standard also establishes
presentation and disclosure requirements designed to facilitate comparison between entities that
choose different measurement attributes for similar types of assets and liabilities. If the fair
value option is elected, the effect of the first remeasurement to fair value is reported as a
cumulative effect adjustment to the opening balance of retained earnings. The statement is to be
applied prospectively upon adoption. SFAS No. 159 is effective for fiscal years beginning after
November 15, 2007. We plan to adopt SFAS No. 159 as of January 1, 2008, and are currently
evaluating the impact of SFAS No. 159 on our results of operations or financial position.
In June 2007, the EITF reached a consensus on EITF Issue No. 07-03, Accounting for
Nonrefundable Advance Payments for Goods or Services to Be Used in Future Research and Development
Activities. EITF 07-03 concludes that non-refundable advance payments for future research and
development activities should be deferred and capitalized until the goods have been delivered or
the related services have been performed. If an entity does not expect the goods to be delivered or
services to be rendered, the capitalized advance payment should be charged to expense. This
consensus is effective for financial statements issued for fiscal years beginning after
December 15, 2007, and interim periods within those fiscal years. Earlier adoption is not
permitted. The effect of applying the consensus will be prospective for new contracts entered into
on or after that date. We do not believe that adoption of the consensus in the first quarter of
2008 will have a material impact on our consolidated financial statements.
Recently Adopted Accounting Standards
We adopted FIN 48, Accounting for Uncertainty in Income Taxes an Interpretation of FASB
Statement 109 on January 1, 2007. FIN 48 clarifies the accounting and reporting for uncertainties
in income tax law. This Interpretation prescribes a comprehensive model for the financial statement
recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected
to be taken in income tax returns. See Note 7 for information pertaining to the effects of adoption
on our consolidated balance sheet.
In February 2006, the FASB issued SFAS No. 155, Accounting for Certain Hybrid Financial
Instruments, which amends SFAS No. 133, Accounting for Derivative Instruments and Hedging
Activities and SFAS No. 140, Accounting for Transfers and Servicing of Financial Assets and
Extinguishments of Liabilities. SFAS No. 155 simplifies the accounting for certain derivatives
embedded in other financial instruments by allowing them to be accounted for as a whole if the
holder elects to account for the whole instrument on a fair value basis. SFAS No. 155 also
clarifies and amends certain other provisions of SFAS No. 133 and SFAS No. 140. SFAS No. 155 is
effective for all financial instruments acquired, issued or subject to a remeasurement event
occurring in fiscal years beginning after September 15, 2006. The adoption of SFAS No. 155 did not
have any impact on our financial position, results of operations or cash flows.
In June 2006, the FASB ratified the consensus on Emerging Issue Task Force (EITF) Issue No.
06-03, How Taxes Collected from Customers and Remitted to Governmental Authorities Should Be
Presented in the Income Statement. The scope of EITF Issue No. 06-03 includes any tax assessed by a
governmental authority that is directly imposed on a revenue-producing transaction between a seller
and a customer and may include, but is not limited to, sales, use, value added, Universal Service
Fund (USF) contributions and some excise taxes. The Task Force affirmed its conclusion that
entities should present these taxes in the income statement on either a gross or a net basis, based
on their accounting policy, which should be disclosed pursuant to Accounting Principles Board
(APB) Opinion No. 22, Disclosure of Accounting Policies. If such taxes are significant, and are
presented on a gross basis, the amounts of those taxes should be disclosed. The consensus on Issue
No. 06-03 is effective for interim and annual reporting periods beginning after December 15, 2006.
As required by EITF 06-03, we adopted this new accounting standard for the interim period beginning
January 1, 2007. The adoption of EITF 06-03 did not have any impact on our financial position,
results of operations or cash flows.
In December 2006, the FASB issued FASB Staff Position (FSP) No. EITF 00-19-2, Accounting for
Registration Payment Arrangements. This FSP specifies that the contingent obligation to make future
payments or otherwise transfer consideration under a registration payment arrangement, whether
issued as separate agreement or included as a provision of a financial instrument or other
agreement, should be separately recognized and measured in accordance with FASB Statement No. 5,
Accounting for Contingencies. The guidance in this FSP amends FASB Statement No. 133, Accounting
for Derivative Financial Instruments and Hedging Activities, and No. 150,
41
Accounting for Certain Financial Instruments with Characteristics of both Liabilities and
Equity and FIN 45, Guarantors Accounting and Disclosure Requirements for Guarantees, Including
Indirect Guarantees of Indebtedness of Others to include scope exceptions for registration payment
arrangements. This FSP is effective immediately for registration payment arrangements and the
financial instruments subject to those arrangements that are entered into or modified subsequent to
the date of issuance of this FSP. For registration payment arrangements and financial instruments
subject to those arrangements that were entered into prior to the issuance of this FSP, this
guidance is effective for financial statements issued for fiscal years beginning after December 15,
2006, and interim periods within those fiscal years. As required by EITF 00-19-2, we adopted this
new accounting standard on January 1, 2007. The adoption of EITF 00-19-2 did not have any impact on
our financial position, results of operations or cash flows.
SPECIAL STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This report contains forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. You can identify these statements by forward-looking words such as may, could,
should, would, intend, will, expect, anticipate, believe, estimate, continue or
similar words. You should read statements that contain these words carefully because they discuss
our future expectations, contain projections of our future results of operations or of our
financial condition or state other forward-looking information. There may be events in the future
that we are not able to predict accurately or control and that may cause our actual results to
differ materially from the expectations we describe in our forward-looking statements. We caution
investors that all forward-looking statements involve risks and uncertainties, and actual results
may differ materially from those we discuss in this report. These differences may be the result of
various factors, including those factors described in Part I, Item 1A, Risk Factors, of our
Annual Report on Form 10-K for the fiscal year ending December 31, 2006, as amended, and other risk
factors identified herein or from time to time in our periodic filings with the SEC. Some important
factors that could cause our actual results to differ materially from those projected in any such
forward-looking statements are as follows:
|
|
|
economic factors, including inflation and fluctuations in interest rates and foreign
currency exchange rates, and the potential effect of such fluctuations on revenues,
expenses and resulting margins; |
|
|
|
|
competitive factors, including technological advances achieved and patents attained by
competitors and generic competition; |
|
|
|
|
domestic and foreign healthcare changes resulting in pricing pressures, including the
continued consolidation among healthcare providers, trends toward managed care and
healthcare cost containment and government laws and regulations relating to sales and
promotion, reimbursement and pricing generally; |
|
|
|
|
government laws and regulations affecting domestic and foreign operations, including
those relating to trade, monetary and fiscal policies, taxes, price controls, regulatory
approval of new products and licensing; |
|
|
|
|
manufacturing interruptions, delays or capacity constraints or lack of availability of
alternative sources for components for our products, including our ability to successfully
maintain relationships with suppliers, or to put in place alternative suppliers on terms
that are acceptable to us; |
|
|
|
|
difficulties inherent in product development, including the potential inability to
successfully continue technological innovation, complete clinical trials, obtain regulatory
approvals or clearances in the United States and abroad, gain and maintain market approval
or clearance of products and the possibility of encountering infringement claims by
competitors with respect to patent or other intellectual property rights which can preclude
or delay commercialization of a product; |
|
|
|
|
significant litigation adverse to us, including product liability claims, patent
infringement claims and antitrust claims; |
42
|
|
|
our ability to comply with regulatory requirements, including the outcome of the
Securities and Exchange Commissions, or the SECs, ongoing investigation into the revenue
recognition issues at our Wampole subsidiary disclosed in June 2005 and the ongoing inquiry
by the Federal Trade Commission, or the FTC, of our acquisition of the Innovacon business; |
|
|
|
|
product efficacy or safety concerns resulting in product recalls or declining sales; |
|
|
|
|
the impact of business combinations, including acquisitions and divestitures; |
|
|
|
|
the impact of our joint venture transaction with The Procter & Gamble Company, or P&G,
on our future financial performance; |
|
|
|
|
our ability to successfully put to use the proceeds we received in connection with the
formation of our joint venture with P&G; |
|
|
|
|
our ability to manage our substantial level of indebtedness and to satisfy the
financial covenants and other conditions contained in the agreements governing our
indebtedness; |
|
|
|
|
our ability to obtain required financing on terms that are acceptable to us; and |
|
|
|
|
the issuance of new or revised accounting standards by the American Institute of
Certified Public Accountants, the Financial Accounting Standards Board, the Public Company
Accounting Oversight Board or the SEC. |
The foregoing list sets forth many, but not all, of the factors that could impact upon our
ability to achieve results described in any forward-looking statements. Readers should not place
undue reliance on our forward-looking statements. Before you invest in our common stock, you should
be aware that the occurrence of the events described above and elsewhere in this report could harm
our business, prospects, operating results and financial condition. We do not undertake any
obligation to update any forward-looking statements as a result of future events or developments.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The following discussion about our market risk disclosures involves forward-looking
statements. Actual results could differ materially from those discussed in the forward-looking
statements. We are exposed to market risk related to changes in interest rates and foreign currency
exchange rates. We do not use derivative financial instruments for speculative or trading purposes.
Interest Rate Risk
We are exposed to market risk from changes in interest rates primarily through our investing
and financing activities. In addition, our ability to finance future acquisition transactions or
fund working capital requirements may be impacted if we are not able to obtain appropriate
financing at acceptable rates.
Our investing strategy, to manage interest rate exposure, is to invest in short-term, highly
liquid investments. Our investment policy also requires investment in approved instruments with an
initial maximum allowable maturity of eighteen months and an average maturity of our portfolio that
should not exceed six months, with at least $500,000 cash available at all times. Currently, our
short-term investments are in money market funds with original maturities of 90 days or less. At
September 30, 2007, our short-term investments approximated market value.
At September 30, 2007, we had a term loan in the amount of $898.0 million and a revolving line
of credit available to us of up to $150.0 million, of which $41.0 million was outstanding as of
September 30, 2007, under our First Lien Credit Agreement. Interest on the term loan, as defined in
the credit agreement, is as follows: (i) in the case of Base Rate Loans, at a rate per annum equal
to the sum of the Base Rate and the Applicable Margin, each as in effect from time to time, (ii) in
the case of Eurodollar Rate Loans, at a rate per annum equal to the sum of the Eurodollar Rate and
the Applicable Margin, each as in effect for the applicable Interest Period, and (iii) in the case
43
of other Obligations, at a rate per annum equal to the sum of the Base Rate and the Applicable
Margin for Revolving Loans that are Base Rate Loans, each as in effect from time to time.
Applicable margin with respect to Base Rate Loans is 1.00% and with respect to Eurodollar Rate
Loans is 2.00%. Applicable margin ranges for our revolving line of credit with respect to Base Rate
Loans is 0.75% to 1.25% and with respect to Eurodollar Rate Loans is 1.75% to 2.25%.
At September 30, 2007, we also had a term loan in the amount of $250.0 million under our
Second Lien Credit Agreement. Interest on this term loan, as defined in the credit agreement, is as
follows: (i) in the case of Base Rate Loans, at a rate per annum equal to the sum of the Base Rate
and the Applicable Margin, each as in effect from time to time, (ii) in the case of Eurodollar Rate
Loans, at a rate per annum equal to the sum of the Eurodollar Rate and the Applicable Margin, each
as in effect for the applicable Interest Period, and (iii) in the case of other Obligations, at a
rate per annum equal to the sum of the Base Rate and the Applicable Margin for Base Rate Loans, as
in effect from time to time. Applicable margin with respect to Base Rate Loans is 3.25% and with
respect to Eurodollar Rate Loans is 4.25%.
In August 2007, we entered into interest rate swap contracts, with an effective date of
September 28, 2007, that have a total notional value of $350.0 million and have a maturity date of
September 28, 2010. These interest rate swap contracts will pay us variable interest at the
three-month LIBOR rate, and we will pay the counterparties a fixed rate of 4.85%. These interest
rate swap contracts were entered into to convert $350.0 million of the $1.3 billion variable rate
term loan under the senior credit facility into fixed rate debt. Based on the terms of the interest
rate swap contracts and the underlying debt, these interest rate swap contracts were determined to
be effective, and thus qualify as a cash flow hedge under SFAS No. 133. As such, any changes in the
fair value of these interest rate swaps are recorded in other comprehensive income on the
accompanying consolidated balance sheet until earnings are affected by the variability of cash
flows.
Assuming no changes in our leverage ratio, which would affect the margin of the interest rates
under the credit agreements, the effect of interest rate fluctuations on outstanding borrowings as
of September 30, 2007 over the next twelve months is quantified and summarized as follows (in
thousands):
|
|
|
|
|
|
|
Interest |
|
|
|
Expense |
|
|
|
Increase |
|
Interest rates increase by 1 basis point |
|
$ |
11,888 |
|
Interest rates increase by 2 basis points |
|
$ |
23,776 |
|
Foreign Currency Risk
We face exposure to movements in foreign currency exchange rates whenever we, or any of our
subsidiaries, enter into transactions with third parties that are denominated in currencies other
than our, or its, functional currency. Intercompany transactions between entities that use
different functional currencies also expose us to foreign currency risk. During the three and nine
months ended September 30, 2007, the net impact of foreign currency changes on transactions was a
gain of $1.3 million and $2.6 million, respectively. The foreign currency gain for the nine months
ended September 30, 2007 included a $1.9 million gain on the settlement of intercompany notes.
Generally, we do not use derivative financial instruments or other financial instruments with
original maturities in excess of three months to hedge such economic exposures. During the three
and nine months ended September 30, 2006, the net impact of foreign currency changes on
transactions was a loss of $0.1 million and a gain of $3.2 million, respectively. The foreign
currency gain for the nine month ending September 30, 2006 included the impact of a $4.3 million
gain resulting from the closure of our CDIL operation in Galway, Ireland.
Gross margins of products we manufacture at our European plants and sell in U.S. Dollar are
also affected by foreign currency exchange rate movements. Our gross margin on total net product
sales was 49.0% for the three months ended September 30, 2007. If the U.S. Dollar had been stronger
by 1%, 5% or 10%, compared to the actual rates during the three months ended September 30, 2007,
our gross margin on total net product sales would have been 49.1%, 49.4%, and 49.9%, respectively.
Our gross margin on total net product sales was 46.8% for the nine months ended September 30, 2007.
If the U.S. Dollar had been stronger by 1%, 5% or 10%, compared to the actual rates during the nine
months ended September 30, 2007, our gross margin on total net product sales would have been 47.0%,
47.6%, and 48.3%, respectively.
In addition, because a substantial portion of our earnings is generated by our foreign
subsidiaries, whose functional currencies are other than the U.S. Dollar (in which we report our
consolidated financial results), our earnings could be materially impacted by movements in foreign
currency exchange rates upon the translation of the earnings of such subsidiaries into the U.S.
Dollar. If the U.S. Dollar had been stronger by 1%, 5% or 10%, compared to the actual average
exchange rates used to translate the financial results of our foreign subsidiaries, our net revenue
and net loss would have been lower by approximately the following amounts (in thousands):
44
|
|
|
|
|
|
|
|
|
|
|
Approximate |
|
Approximate |
|
|
decrease in net |
|
increase in net |
If, during the three months ended September 30, 2007, the U.S. dollar was stronger by: |
|
revenue |
|
loss |
1% |
|
$ |
357 |
|
|
$ |
36 |
|
5% |
|
$ |
1,785 |
|
|
$ |
182 |
|
10% |
|
$ |
3,570 |
|
|
$ |
364 |
|
|
|
|
|
|
|
|
|
|
|
|
Approximate |
|
Approximate |
|
|
decrease in net |
|
increase in net |
If, during the nine months ended September 30, 2007, the U.S. dollar was stronger by: |
|
revenue |
|
loss |
1% |
|
$ |
1,378 |
|
|
$ |
123 |
|
5% |
|
$ |
6,888 |
|
|
$ |
615 |
|
10% |
|
$ |
13,776 |
|
|
$ |
1,231 |
|
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management evaluated, with the participation of our Chief Executive Officer (CEO) and
Chief Financial Officer (CFO), the effectiveness of the design and operation of our companys
disclosure controls and procedures (as defined in Rules 13a
15(e) or 15d 15(e) under the
Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly
Report on Form 10-Q. Based on this evaluation, our management, including the CEO and CFO, concluded
that our companys disclosure controls and procedures were effective at that time. We and our
management understand nonetheless that controls and procedures, no matter how well designed and
operated, can provide only reasonable assurances of achieving the desired control objectives, and
our management necessarily was required to apply its judgment in evaluating and implementing
possible controls and procedures. In reaching their conclusions stated above regarding the
effectiveness of our disclosure controls and procedures, our CEO and CFO concluded that such
disclosure controls and procedures were effective as of such date at the reasonable assurance
level.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting that occurred during the
period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably
likely to materially affect, our internal control over financial reporting.
PART II OTHER INFORMATION
Item 1A. Risk Factors
Other than as set forth below, there have been no material changes in the Risk Factors
described in Part I, Item 1A (Risk Factors) of our Annual Report on Form 10-K, as amended, for
the year ended December 31, 2006 (the Form 10-K) or in Part II, Item 1A, Risk Factors, of any
subsequent Quarterly Report on Form 10-Q.
Acquisition
of HemoSense
On
November 6, 2007, we completed our previously announced
acquisition of HemoSense, Inc.
Pending
Acquisition of Alere
On October 24, 2007, we entered into a merger agreement pursuant to which we will acquire
Alere. The completion of the merger is subject to various customary closing conditions.
Alere is in the business of providing health
management services to patients with chronic illnesses, a business which differs significantly from our
core professional and consumer diagnostic product businesses. Although we intend to retain the senior management team and substantially all of the employees of Alere following the acquisition, we do not have substantial experience
in Aleres business sector. Accordingly, we may not be able to compete in this sector as effectively
as more experienced competitors.
The risk factors set forth in the Form 10-K relating to acquisitions and the integration of
acquired businesses apply to our recently acquired and pending acquisitions. This includes the
risk that, through acquired businesses, we may assume significant liabilities, including lawsuits or
other claims. For example, HemoSense and Alere are both subject to lawsuits, including lawsuits
relating to intellectual property rights. As the acquiror of HemoSense and Alere, we assume
responsibility for the cost of defending these lawsuits once these transactions are completed.
These lawsuits could be expensive and while we anticipate that the resolution of these lawsuits
would not have a material adverse impact on our financial condition, an adverse determination could
materially and adversely impact the acquired business.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
On July 27, 2007, we issued a total of 40,186 shares of common stock, as consideration for the
acquisition of all of the capital stock of Spectral Diagnostics Private Limited and Source
Diagnostics (India) Private Limited, pursuant to an exemption afforded by Section 4(2) of the
Securities Act of 1933, as amended.
45
ITEM 6. EXHIBITS
Exhibits:
|
|
|
Exhibit No. |
|
Description |
10.1
|
|
Lease Agreement between Cholestech Corporation and the BIV Group dated July 23, 2001 |
|
|
|
10.2
|
|
Lease Agreement Addendum No. One by and between Cholestech Corporation and BIV
Group dated November 19, 2004 |
|
|
|
31.1
|
|
Certification by Chief Executive Officer Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002 |
|
|
|
31.2
|
|
Certification by Chief Financial Officer Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002 |
|
|
|
32.1
|
|
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 |
46
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
INVERNESS MEDICAL INNOVATIONS, INC.
|
|
|
|
|
|
|
|
Date: November 8, 2007
|
|
/s/ DAVID TEITEL |
|
|
|
|
|
|
|
|
|
David Teitel |
|
|
|
|
Chief Financial Officer and an authorized officer |
|
|
47